<allTrials totalCount="195" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2026-11-19T16:53:04.916313891Z" version="10" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN13310937" publicIdentifierDateAssigned="2026-11-19T16:53:05.040461Z">
    <isrctn dateAssigned="2026-11-19T16:53:05.040461Z">13310937</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study testing a weight management programme for adults with cystic fibrosis</title>
      <scientificTitle>A randomised feasibility study to test a cystic fibrosis specific weight management programme alongside an NHS digital weight management programme (MoreLife®-CF) compared to delivering an NHS digital weight management programme only (MoreLife®) in adults with cystic fibrosis (the MoreLife®-CF feasibility study)</scientificTitle>
      <acronym/>
      <studyHypothesis>1. To assess the feasibility of the study procedures
2. To assess the feasibility of intervention delivery within adult CF centre care
3. To assess participant engagement with the study procedures
4. To assess participant engagement with MoreLife®-CF intervention
5. To assess participants' and CF healthcare professionals' (HCPs') perceived acceptability of the study procedures
6. To assess participants' and CF HCPs' perceived acceptability of MoreLife®-CF</studyHypothesis>
      <plainEnglishSummary>Background and study aims 
Cystic fibrosis (CF) is a life-limiting genetic condition that affects the lungs and digestive system. People with CF were encouraged to eat a high-calorie diet because gaining weight was difficult and being well nourished helps them stay healthier. New treatments have now improved their health, but some adults with CF are becoming overweight or obese and they now require support to manage their weight.
This study will test whether it is feasible to deliver a CF-specific digital weight management programme (MoreLife® CF) alongside an NHS digital weight management programme (MoreLife®). We want to understand whether the study design and the MoreLife® CF programme can be delivered in CF services, whether it is more acceptable, useful and interesting to people with CF than the NHS MoreLife® only, and whether a future larger trial would be possible.

Who can participate? 
Patients aged 18 years and over with CF who are overweight or obese

What does the study involve? 
Participants will be allocated by chance into two groups: one group will receive MoreLife® CF and the other will receive the NHS MoreLife® only. The study will last 16 weeks. Before and after taking part in the programmes, participants will have their height, weight, waist, body composition and handgrip strength measured. They will complete some questionnaires about their wellbeing, knowledge and approach to behaviour change. They will also record what they eat, and wear an activity monitor. At the end of the study, participants and the dietitians who delivered the programmes will be invited to interviews to share their views on taking part and how acceptable and engaging they found the study procedures and the MoreLife® CF programme.

What are the possible benefits and risks of participating? 
Taking part in this study may help adults with CF learn new ways to manage their diet, weight and physical activity. It will also provide them with access to useful educational resources about healthy eating and physical activity suitable for adults with CF. Participation in the study will also help researchers improve future weight management support for adults with cystic fibrosis.
Taking part will require time and commitment, and some people may find discussing their experiences or completing study activities emotionally challenging. The programme aims to support healthy weight loss, but any concerns about weight loss, physical and mental health, or wellbeing will be monitored by the participants CF team. Adults with CF who are pregnant are not eligible to participate. Continued participation will be reviewed if they become pregnant during the study.

Where is the study run from? 
University of Birmingham (UK)

When is the study starting and how long is it expected to run for? 
March 2027 to March 2028

Who is funding the study? 
National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?
Joanne Barrett, joanne.barrett2@nhs.net</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>1. Feasibility of study procedures:
1.1. Proportion of eligible participants who were recruited and successfully randomised. In those who declined participation, reasons for declining (captured via a decliner questionnaire)
1.2. Proportion of participants who completed the study/did not complete the study and reasons for withdrawal from the study
1.3. Proportion of participants who had demographic, clinical and anthropometric measurements and recorded and questionnaires administered at baseline and follow up

2. Feasibility of intervention delivery:
2.1. Proportion of participants who received intervention components (e.g., were able to access the MoreLife®-CF platform and MoreYou app, one-to-one sessions with CF dietitian, weekly text messages sent out by NHS locations, invitation to online peer group sessions, additional ad hoc support provided by CF dietitian if requested) 
2.2. Proportion of intervention components delivered as planned by dietitian at recruiting NHS locations

3. Engagement with the study procedures
3.1. Proportion of patients who attended study visits 
3.2. Proportion of participants who adhered to study procedures; completed a food diary (&gt;3 days), completed physical activity monitoring (&gt;4 days &gt;10 hours/day), completed questionnaires and attended for interview

4. Engagement with the intervention (MoreLife®-CF):
4.1. Proportion of participants who completed the programme and did not complete the programme
4.2. Proportion of participants who engaged with the MoreLife®-CF platform and MoreLife® MoreYou app; frequency and number of logins, time spent on platform pages, number of and type of information downloads, activities completed, e.g., smart goals, action planning
4.3. Proportion of participants who self-monitor weight, diet, and physical activity
4.4. Proportion of participants who attended one-to-one CF dietitian consultations
4.5. Proportion of participants who attended online peer group sessions

5. Acceptability of the study procedures:
5.1. Participants' views of the acceptability of the randomisation, the number of study visits and the format of these visits, e.g., in person/virtual, anthropometric measurements, food intake monitoring, physical activity monitoring, and questionnaires administered
5.2. CF dietitians' views of the acceptability of the randomisation process, the number of study visits and the format of these visits, e.g., in person/virtual, anthropometric measurements, food intake monitoring, physical activity monitoring devices and questionnaires, intervention training

6. Acceptability of the intervention (MoreLife®-CF):
6.1. Participants' views and opinions on the acceptability of the MoreLife®-CF platform, resources, and activities
6.2. Participants' views and opinions of CF dietitian support (one-to-one consultations, text message check ins, ad hoc support and online group sessions)
6.3. CF dietitians' views and opinions on the acceptability of delivery and the relevance of MoreLife®-CF in adult CF centre care

Timepoint(s): 12 weeks post commencement of intervention</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>Measured at weeks 0 and 15:
1. Dietary intake in relation to personalised goals measured by total energy (calorie intake), macronutrient intake as a percentage of energy (protein, fat and carbohydrate), free sugar intake as a percentage of energy, fibre as measured in grams per day and fruit and vegetable intake as measured in portions per day
2. Physical activity measured in relation to personalised goals as measured as time spent sedentary, light, moderate and vigorous activity intensities
3. Weight (kg) and body mass index (kg/m2)
4. Handgrip strength measured in kg
5. Waist circumference measured in cm
6. Body composition measured by percentage fat mass, percentage fat-free mass and fat-free mass index 
7. Perceived capabilities, opportunities and motivations 
8. Questionnaire scores:
8.1. Depression and anxiety measured using the Patient Health Questionnaire 9 (PHQ-9) and the Generalized Anxiety Disorder 7 (GAD-7) questionnaire
8.2. CF-specific wellness measured using the Alfred Wellness Score (AWESCORE)
8.3. Digital health literacy measured using the Electronic Health Literacy Scale (eHEALS)
8.4. Healthy eating and weight self-efficacy measured using the Healthy Eating and Weight Self-Efficacy (HEWSE) Scale
8.5. Theory of Planned Behaviours constructs attitudes towards the diet and physical activity behaviours, subjective norms (injunctive and descriptive norms), perceived behavioural control, behavioural intentions, and self-reported behaviour for both healthy eating and physical activity</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="38500344-00f5-4416-9c4d-e4f21fd206d3" approvalStatus="notYetSubmitted">
	  <committeeName/>
	  <contactDetails>
	    <address/>
	    <city/>
	    <state/>
	    <country/>
	    <zip/>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference/>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13310937</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 74330, NIHR: 302884</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="697c0d80-a950-4ad9-b442-d203e412a4a2" numberType="cpms" canonicalSecondaryNumber="CPMS74330">74330</secondaryNumber>
	<secondaryNumber id="1f7109fb-ba41-495c-b42f-20105b01eb5e" numberType="nihr" canonicalSecondaryNumber="NIHR302884">302884</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2028-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a4e9b54a-8ab5-4f83-84fd-4f207ed11756">
	  <name>West Midlands Adult Cystic Fibrosis Centre, University Hospitals Birmingham NHS Foundation Trust</name>
	  <address>Heartlands Hospitals
Bordesley Green East</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B9 5SS</zip>
	  <rtsId>RRK@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="f9212726-b6c9-473e-a73d-512b1fc0a3f6">
	  <name>Sheffield Adult CF Centre, Sheffield Teaching Hospitals NHS Foundation Trust</name>
	  <address>Northern General Hospital
Herries Road</address>
	  <city>Sheffield</city>
	  <state/>
	  <country>England</country>
	  <zip>S5 7AU</zip>
	  <rtsId>RHQ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="0a4b36ed-33ce-4e1c-a0e9-1f5fab1225b2">
	  <name>Wolfson Cystic Fibrosis Centre, Nottingham University Hospitals NHS Trust</name>
	  <address>Nottingham City Hospital
St Francis Way</address>
	  <city>Nottingham</city>
	  <state/>
	  <country>England</country>
	  <zip>NG5 1PF</zip>
	  <rtsId>RX1@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1e401558-ad51-4810-a3e0-0017a02c4333">
	  <name>Newcastle Adult Cystic Fibrosis Centre, Royal Victoria Infirmary</name>
	  <address>Queen Victoria Road</address>
	  <city>Newcastle upon Tyne</city>
	  <state/>
	  <country>England</country>
	  <zip>NE1 4LP</zip>
	  <rtsId>RTD@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Registered at recruiting site
2. Confirmed diagnosis of CF with genotype
3. Clinically stable (no respiratory exacerbation within previous) 28 days
4. Aged &gt;18 years
5. Body mass index (BMI) &gt;25 kg/m2
6. Prescribed or self-funded GIP-1, GIP dual receptor agonist medications for weight loss or diabetes management, e.g., tirzepatide,semaglutide
7. Digital smartphone and web access
8. Able to give informed consent</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Pregnant
2. Diagnosis of an eating disorder 
3. Currently a hospital inpatient 
4. Currently being screened for cystic fibrosis–related diabetes (CFRD) using flash glucose monitoring at time of recruitment
5. Currently receiving treatment for distal intestinal obstruction syndrome (DIOS) or acute constipation at time of recruitment
6. Currently receiving oral or IV antibiotics for respiratory exacerbation at time of recruitment
7. Currently prescribed an increased dose of glucocorticoid (above usual maintenance dose) at time of recruitment</exclusion>
      <recruitmentStart>2027-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cystic fibrosis (CF)</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is a non-blinded randomised mixed-methods feasibility study.

Following informed consent, participants will undertake four study visits. At visit 1 pre-intervention data will be collected,  at visit 2 participants will be randomised to the intervention or control arm, at visit 3 post-intervention data will be collected,  and at visit 4 post-intervention and control study interviews will be conducted.

Study  Visit 1 - baseline data collection (week 0, pre-intervention):
Visit 1 will take place at the recruiting NHS study location and the following data will be collected:

Demographic and clinical data:
Data recorded from participants medical notes; participants; age, sex, ethnicity, CF genotype and microbiology, comorbidities, lung function (actual and % predicted Fev1 best within previous 6 months and postcode), household income and employment/education status.

Anthropometric and handgrip data:
Participants will have their weight, height, waist circumference, handgrip strength and body composition measured. 

Dietary intake and physical activity data:
1. Food diary: participants will be asked to record their food intake for 7 consecutive days using the MyFood24® smartphone application or paper food diary. 
2. Physical activity monitoring: participants will be provided with a wrist worn accelerometer monitor to wear for 7 consecutive days (at the same time of completing the food diary). Participants will be advised to wear the monitor for as many hours as they can each day, ideally for at least 10 hours per day. They can also wear it when they are asleep. 

Questionnaires:
Participants complete seven questionnaires:
1. Patient Health Questionnaire 9 (PHQ-9) and  Generalized Anxiety Disorder 7 (GAD-7)
2. CF-specific Alfred Wellness Score (AWESCORE)
3. Digital health literacy e-Heals
4. Healthy Eating and Weight Self-Efficacy Scale (HEWSE)
5. A study-specific healthy eating and physical activity knowledge questionnaire
6. A study-specific Theory of Planned Behaviour  questionnaire to assess the five core TPB constructs: attitudes towards the behaviour, subjective norms, perceived behavioural control, behavioural intentions, and self-reported behaviour for both healthy eating and physical activity. 

Visit 2 – Randomisation, commencement of intervention (week 2):
Randomisation:
Participants will be randomised to the intervention MoreLife®-CF (the CF-specific weight management intervention + the NHS digital weight management intervention MoreLife®) or the control arm (the NHS digital weight management intervention MoreLife®). Both of these programmes will last for 12 weeks.

Intervention arm (MoreLife®-CF):
The intervention (MoreLife®-CF) will comprise a one-on-one consultation with their CF dietitian at the start of the intervention to set personalised goals, an action plan and adjustment plan. These will be reviewed at one-to-one follow-up visits during weeks 4, 8 and 12 of the intervention.

 Following the first one-to-one consultation they will be provided with  access to the MoreLife®-CF platform and the NHS digital weight management programme MoreLife® via the MoreYou app.

A weekly text message will be sent to each participant during the 12-week intervention from their CF dietitian, and they will be invited to attend  online group/peer support sessions. 

Control arm (MoreLife®):
Participants will be invited to a one-to-one consultation with a CF dietitian at week 0 of the intervention. Following the first one-to-one consultation they will be provided with  access to the NHS digital weight management programme (MoreLife®) via the MoreYou app.
	
Visit 3 - post intervention data collection (week 13):
All measures undertaken during visit 1 will be repeated at the end of the intervention at the participants recruiting location. 

Visit 4 -  participant post-intervention interview for intervention and control arm participants (weeks 15):
Online or in person semi-structured interviews will be conducted with both intervention and control participants by the CI and will explore participant’s experiences of taking part in the study, including their views on study procedures and methods of data collection, reasons for completion/non-completion of the programme, acceptability and engagement with the MoreLife®-CF intervention, and how it can be improved (intervention participants only).  

CF dietitian focus group interviews:
All CF dietitians who have delivered the intervention will be invited to participate in a online focus group to explore their views on methods of study delivery, reasons for completion/non-completion of the programmes by participants, the feasibility of delivering MoreLife® in adult CF centre care and acceptability and engagement with the intervention (MoreLife®-CF) and NHS digital weight management intervention (MoreLife®) by participants.  They will also be asked to provide feedback on how MoreLife®-CF could be improved.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study will be available upon request</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Available on request</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>d3622e4d-ece3-494c-9231-a73189f72b05</funderId>
      <contactId>7fd50655-882e-4c55-bf49-6283bcdf7043</contactId>
      <sponsorId>5e2e6eb7-7933-4528-b22f-bed3a68f99c8</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="7fd50655-882e-4c55-bf49-6283bcdf7043">
    <title>Mrs</title>
    <forename>Joanne</forename>
    <surname>Barrett</surname>
    <orcid>https://orcid.org/0000-0002-5601-4028</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>West Midlands Adult Cystic Fibrosis Centre, Ward 26, Bordesley Green East</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>-B9 5SS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 424 1788</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joanne.barrett2@nhs.net</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="5e2e6eb7-7933-4528-b22f-bed3a68f99c8">
    <organisation>University of Birmingham</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/03angcq70</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="d3622e4d-ece3-494c-9231-a73189f72b05">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-19T16:05:47.387097306Z" version="15" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN14336073" publicIdentifierDateAssigned="2026-11-19T16:05:47.520421Z">
    <isrctn dateAssigned="2026-11-19T16:05:47.520421Z">14336073</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>Short bouts of daily movement for people with chronic low back pain</title>
      <scientificTitle>Snacktivity and brief movement for everyday life in people with chronic low back pain</scientificTitle>
      <acronym>Snacktivity LBP</acronym>
      <studyHypothesis>Primary Aim:
The primary objective of this randomised pilot study is to assess the feasibility and acceptability of delivering a values‑informed Snacktivity intervention to adults with CLBP within a parallel‑group randomised design. 

Secondary Objectives:
To explore changes in:
1. Recruitment and retention rates 
2. Self‑efficacy for brief movement 
3. Hope, adaptation and emotional responses 
4. Engagement in brief bouts of daily movement
5. To examine participant experiences of Snacktivity intervention considering pain management, daily routines, and perceived burden
6. To generate preliminary data to inform a future controlled trial</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Chronic low back pain is common and can make it difficult for people to stay active. Although physical activity is recommended, many people find structured exercise programmes difficult to follow due to pain, fatigue, or lack of confidence.
This study aims to test whether a different approach encouraging very short, flexible bouts of movement throughout the day (“Snacktivity”) is practical, acceptable, and potentially helpful for people with chronic low back pain.

Who can participate?
Adults aged 18 years or older with chronic low back pain lasting longer than 3 months can take part. Participants must be living independently and able to engage in light movement. People with serious spinal conditions, specific causes of back pain, or major health issues that limit movement will not be eligible.

What does the study involve?
Participants will be randomly allocated to one of two groups:
1. A Snacktivity group, involving a 6-week programme encouraging short, frequent movement in daily life, supported by an introductory session and weekly check-ins
2. A comparison group, receiving standard advice for managing low back pain
Participants will complete questionnaires at the start of the study, after 6 weeks, and at a 12-week follow-up. Some participants may also take part in interviews about their experiences.

What are the possible benefits and risks of participating?
Participants may benefit from increased confidence, improved understanding of movement, and a better ability to manage daily activity with back pain.
Risks are expected to be low but may include temporary increases in pain, discomfort, or fatigue when moving. Participants are encouraged to adapt or stop activities if needed.

Where is the study run from?
The study is run from the University of Birmingham (UK), with participation taking place in the community and/or online.

When is the study starting and how long is it expected to run for?
September 2026 to October 2027

Who is funding the study?
University of Birmingham (UK)

Who is the main contact?
Dr Andrew Soundy, A.A.Soundy@bham.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="25900e89-2e94-4009-ac1d-6e096ad58470">
	  <variable>Feasibility outcomes (recruitment, retention, adherence, acceptability, and data completeness)</variable>
	  <method>study-specific feasibility data collection forms, recruitment logs, adherence records, and participant feedback questionnaires</method>
	  <timepoints>baseline, 6-week (post-intervention), and 12-week (follow-up)</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome>1. Confidence for engaging in brief movement (Snacktivity-specific self-efficacy) measured using the Snacktivity Self-Efficacy Scale (S-SES) at baseline, 6-week (post-intervention), and 12-week (follow-up)
2. Pain self-efficacy (confidence in functioning despite pain) measured using the Pain Self-Efficacy Questionnaire (PSEQ) at baseline, 6-week (post-intervention), and 12-week (follow-up)
3. Cognitive flexibility (ability to adapt thinking and behaviour) measured using the Cognitive Flexibility Scale at baseline, 6-week (post-intervention), and 12-week (follow-up)
4. Emotion regulation strategies (cognitive reappraisal and expressive suppression) measured using the Emotion Regulation Questionnaire (ERQ) at baseline, 6-week (post-intervention), and 12-week (follow-up)
5. Emotional adaptation to movement-related challenges (hope, adaptation, energy, and emotional valence) measured using the Model of Emotions, Adaptation and Hope (MEAH) questionnaire at baseline, 6-week (post-intervention), and 12-week (follow-up)
6. Low back pain-related disability (functional limitation) measured using the Oswestry Disability Index (ODI) at baseline, 6-week (post-intervention), and 12-week (follow-up)
7. Health-related quality of life (physical and mental health status) measured using the Short Form-12 (SF-12), including Physical Component Summary (PCS) and Mental Component Summary (MCS) scores, at baseline, 6-week (post-intervention), and 12-week (follow-up)</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="6fdcee07-7cf9-4222-bbcd-ceafd712e4d7" approvalStatus="submitted" statusDate="2026-05-15T00:00:00.000Z">
	  <committeeName>University of Birmingham Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>Research Ethics, Governance and Integrity, University of Birmingham, Edgbaston Campus</address>
	    <city>Birmingham</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>B15 2TT</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>ERN_6273</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14336073</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber/>
      <secondaryNumbers/>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Health services research</purpose>
	  <purpose>Supportive care</purpose>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2027-10-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8f0fe570-0355-4887-9e47-00e60ffb8b06">
	  <name>University of Birmingham</name>
	  <address>School of Sport, Exercise and Rehabilitation Sciences
Y14, UoB Edgbaston</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B15 2TT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Adults aged ≥18 years
2. Diagnosis of CLBP (≥3 months duration). CLBP will be defined as pain in the lumbar region persisting for 3 months or longer 
3. Back pain which is not attributable to a specific cause, i.e., people with non-specific CLBP will be recruited
4. Living independently in the community
5. Able to stand and move with or without discomfort and able to engage with light physical movement as part of daily activities
6. Able to provide informed consent</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="88.0">88 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Acute low back pain (&lt;3 months)
2. Serious spinal pathology (e.g., fracture, malignancy, infection) or uncontrolled comorbidities (including major psychiatric conditions, uncontrolled diabetes or heart failure)
3. Specific causes of CLBP, e.g., lumbar radiculopathy
4. Neurological conditions severely limiting movement
5. Current participation in structured exercise rehabilitation (&gt;2 sessions/week)
6. Pregnancy</exclusion>
      <recruitmentStart>2026-09-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-09-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic non-specific low back pain (CLBP)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants will be randomised using a computer-generated random allocation sequence in a 1:1 ratio to either the Snacktivity intervention group or the comparator (usual care) group. Simple randomisation will be used without stratification. Allocation concealment will be ensured through a centralised electronic system, with the allocation sequence generated and stored by a member of the research team not involved in recruitment or baseline assessment. Group allocation will be revealed only after completion of baseline measures.

Participants will be randomly allocated to one of two groups:
1. A Snacktivity group, which includes a 6-week programme with an initial session, weekly check-ins, and guidance on using short movement breaks in daily life
2. A comparison group, which will receive standard advice about managing low back pain

Snacktivity LBP: Brief Movement for Everyday Life Intervention:
This will be a 6-week intervention with baseline, post- and follow-up (12-week) assessments. An initial in-person or online group session will introduce education on Snacktivity principles, the Model of Emotions, Adaptation and Hope (MEAH) and motivational interviewing screening and support, and an introduction to the home-based Snacktivity booklet. Weekly check-in with trained student physiotherapists to identify MEAH ratings and updates around improvement.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="56467691-067d-42c9-9f58-98ed607e35d6" outputType="protocolfile" artefactType="LocalFile" dateCreated="" dateUploaded="2026-05-15T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="35c959b1-4028-40ef-817f-d86086c1b35f" originalFilename="49542_PROTOCOL.pdf" downloadFilename="49542_PROTOCOL.pdf" version="" mimeType="application/pdf" length="4467299" md5sum="0edde8daaf83e5bd42d90af34a374b0b"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>34290beb-d0ac-4df5-8e27-4822b2d79ad5</funderId>
      <contactId>dd8324d2-955d-4f73-a6ce-b0c7c812c7a9</contactId>
      <sponsorId>0991e89c-0c17-49a6-8a62-354094b5c852</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/35c959b1-4028-40ef-817f-d86086c1b35f/49542">
	<description>Protocol file</description>
	<name>49542_PROTOCOL.pdf</name>
	<id>35c959b1-4028-40ef-817f-d86086c1b35f</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>4467299</length>
	<md5sum>0edde8daaf83e5bd42d90af34a374b0b</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="dd8324d2-955d-4f73-a6ce-b0c7c812c7a9">
    <title>Dr</title>
    <forename>Andrew</forename>
    <surname>Soundy</surname>
    <orcid>https://orcid.org/0000-0002-5118-5872</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Y14, University of Birmingham, Edgbaston</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 414 8385</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">A.A.Soundy@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="0991e89c-0c17-49a6-8a62-354094b5c852">
    <organisation>University of Birmingham</organisation>
    <sponsorType/>
    <rorId>https://ror.org/03angcq70</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="34290beb-d0ac-4df5-8e27-4822b2d79ad5">
    <name>University of Birmingham</name>
    <fundRef>http://dx.doi.org/10.13039/501100000855</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-05T08:54:35.29409371Z" version="9" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN15392005" publicIdentifierDateAssigned="2026-11-05T08:54:35.512158Z">
    <isrctn dateAssigned="2026-11-05T08:54:35.512158Z">15392005</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Holistic health and care support for people experiencing homelessness in temporary accommodations (REACH)</title>
      <scientificTitle>Strengths-based, low caseload approach to integrated health, housing and practical support for people experiencing homelessness with multiple complex needs in temporary accommodations: a multi-centre, open-label, cluster randomised controlled trial with embedded economic and qualitative process evaluation</scientificTitle>
      <acronym>REACH</acronym>
      <studyHypothesis>Primary Objective
To reduce the number of Emergency Department (ED) attendances for all causes over 12 months following baseline assessment in the intervention arm compared to usual care arm

Secondary Objectives
1. Improve health and wellbeing (e.g. mortality, physical health, mental health, quality of life EQ-5D-5L, substance including alcohol use)
2. Evaluate impact on healthcare resource use (e.g. ED presentation for overdose, mental health conditions; ambulance call outs, hospitalisation, use of mental health, substance use treatment, harm reduction and nominated pharmacy services) 
3. Improve social outcomes (e.g. employment, housing, criminal justice encounters)
4. Evaluate cost-effectiveness of REACH 
5. To evaluate implementation process, understand mechanisms of impact and acceptability of REACH to study participants, REACH care team, temporary accommodation staff and wider stakeholders (process evaluation)</studyHypothesis>
      <plainEnglishSummary>Background and study aims 
People who experience homelessness (PEH) suffer from poor physical and mental health. Many die in their early 40s as they do not receive timely help and treatment for their health and care needs. Most of these deaths can be prevented. Temporary accommodations (e.g. hostels) are often the first housing support for PEH. Despite housing some of the sickest citizens of society, there is no national guidance to tell us how health and care should be provided to temporary accommodation residents. Many residents with complex health and care issues struggle to move on as they are unable to receive the support they need. One person described to us that they spent 14 years in a hostel, mostly stuck in their room with mental health problems and no support. Many also return to the streets as they lack opportunities, and experience loneliness and boredom. 

This study will test a 'joined-up' way of delivering care in hostels. This has been called 'Reach, Engage and Recovery' (REACH) and it will involve mental health practitioners (e.g. mental health nurses) and care navigators providing support to temporary accommodation residents. 

Who can participate? 
Adults aged 18 or older who are a resident of a temporary accommodation, with one or more of the following: mental health problem, substance (includes alcohol) use, history of criminal justice encounter and/or equal to or longer than 6 months in one stay or repeat stay in temporary accommodations.

What does the study involve? 
The care team will have a low number of people to look after, which allows them to offer focused support for people who have high health and care needs. The care team will check, treat and refer people to improve their physical and mental health, wellbeing, practical skills for recovery and employment. This study will take place across  temporary accommodations for PEH based in London, Midlands, North of England and Scotland. Temporary accommodations will be divided into two groups, with residents of one group receiving the REACH care and the other group receiving the care as usual. 

The REACH group will receive support from the care team for 12 months, allowing rapport building over this period of contact and opportunities to establish positive changes. The REACH team will check residents' physical, mental health, housing, practical needs and provide trauma-informed (being aware of life situations) care. They will work with local community organisations to support skills (e.g. volunteering, gardening, mentoring, arts/crafts, employment training), address loneliness and promote wellbeing. They will focus on individual's strengths and goals as they support long-term recovery. Data will be collected to evaluate whether REACH reduces Emergency Department (A&amp;E) visits, repeat homelessness, offending, resident deaths and improves housing uptake, quality of life and employment. Views will be obtained from PEH and service providers' views about REACH and the study will find out if it saves money for the health and care system. 

The study team have partnered with key national providers of hostels, health services and charities to better understand what is needed to roll out REACH across the UK. Study partners HomelessLink and Pathway will share the study findings with PEH, Government Departments and wider stakeholders. They plan to publish results in scientific journals and present the  findings in forms that are accessible to PEH. 

REACH was co-designed through discussions with members of a lived experience advisory group on homelessness at King's College London. They will remain advisors on the study. The study team also spoke to residents of temporary accommodations as well as frontline staff and managers. Participants recommended that REACH should focus on people who are most likely to fall through the gaps. One of the study's co-applicants has lived experience of homelessness.

What are the possible benefits and risks of participating? 
This study could help improve care for people who are experiencing homelessness. Participants in the intervention arm may receive additional support throughout the study. There are no anticipated risks or disadvantages of taking part in the study. Some questions may be upsetting but these are similar to questions in normal care.

Where is the study run from?  
King's College London, UK.

When is the study starting and how long is it expected to run for? 
March 2027 to October 2029.

Who is funding the study? 
The National Institute for Health and Care Research (NIHR), UK.

Who is the main contact?
Prf Vibhu Paudyal, vibhu.paudyal@kcl.ac.uk.</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="a67d8f9f-f76d-4546-aae0-9412d44e48e8">
	  <variable>Number of ED attendances for all causes during the 12 months following the baseline assessment</variable>
	  <method>data collected from NHS records held centrally in England and Scotland</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="cd4404e8-dd98-4b39-a199-3e223524795a">
	  <variable>All-cause mortality</variable>
	  <method>NHS and temporary accommodation records to count the number of deaths in the 12 months follow up period- data collected</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="27ca2082-b4f4-42b8-859f-273d1fb5c96e">
	  <variable>Quality of life</variable>
	  <method>EQ-5D-5L- data collected via participant self reports</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="5f22e49b-131d-400f-8e1e-6ae1fbf3f505">
	  <variable>Physical health problems or diagnosis</variable>
	  <method>NHS records and participant self reports to count long term physical health problems</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="fac5ae30-af3a-4644-93d6-702dfec7c3a1">
	  <variable>Mental health problems or diagnosis</variable>
	  <method>NHS and participant self reports to count long term mental health problems</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="640b01a0-591c-437b-8401-3bd48001ae85">
	  <variable>Current substance use</variable>
	  <method>ASSIST-LITE scores from participant self reports</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="26bc23cd-3a0f-4e00-bad9-896a2f183508">
	  <variable>Prescribed treatment for diagnosed substance use disorder</variable>
	  <method>whether currently on treatment: data collected via participant self reports, substance use treatment services and temporary accommodation records</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9cada968-e6dc-4761-8d45-24699cf1a7a0">
	  <variable>Self-efficacy</variable>
	  <method>the PROMIS General Self-Efficacy Scale via participant self reports</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="0990fc10-a74b-4656-93fd-a2fafa47d39a">
	  <variable>Capability and wellbeing</variable>
	  <method>the ICEpop CAPability measure for Adults (ICECAP-A) via participant self reports</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c034221e-78c8-4b67-a25d-f1c8819d4812">
	  <variable>Healthcare and resource use over 12 months, accounting for person-years of follow-up, e.g. the number of ED presentations for substance use, number of ambulance call outs,</variable>
	  <method>NHS records, ambulance records, participant self reports and temporary accommodation records</method>
	  <timepoints>12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="044b3670-fba1-4927-a2a5-207c53bd9af1">
	  <variable>Social Outcomes (e.g. current housing status, criminal justice encounters, employment status)</variable>
	  <method>questionnaire completion with participants/temporary accommodation staff</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9f24df3f-9553-4046-aae7-a0aefe639513">
	  <variable>Economic evaluation outcomes [E.g. Cost-effectiveness – incremental cost per QALY gained]</variable>
	  <method>economic evaluation</method>
	  <timepoints>12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c46670df-8d61-420c-87fc-c7c2ffacec16">
	  <variable>Exploratory outcomes (e.g. satisfaction with mental and physical health care, and substance use treatment)</variable>
	  <method>questionnaire completion</method>
	  <timepoints>12 months</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="56aa82d6-05e1-4a90-aa9d-491711430074" approvalStatus="submitted" statusDate="2026-10-15T00:00:00.000Z">
	  <committeeName>Wales REC 1</committeeName>
	  <contactDetails>
	    <address>Health and Care Research Wales, Floor 4, Crown Building</address>
	    <city>Cardiff</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>CF10 3NQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/WA/0317</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15392005</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 68171, NIHR: 174677</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="4f64b7f7-658a-4671-add6-0aa396ed465c" numberType="cpms" canonicalSecondaryNumber="CPMS68171">68171</secondaryNumber>
	<secondaryNumber id="6fec4d14-4a15-4095-8f7e-ad6a6cc0a87e" numberType="nihr" canonicalSecondaryNumber="NIHR174677">174677</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Health services research</purpose>
	  <purpose>Supportive care</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2029-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Scotland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="04ad0090-a3e3-48af-aefc-f30da8355555">
	  <name>South London and Maudsley NHS Foundation Trust</name>
	  <address>Bethlem Royal Hospital
Monks Orchard Road</address>
	  <city>Beckenham</city>
	  <state/>
	  <country>England</country>
	  <zip>BR3 3BX</zip>
	  <rtsId>RV5@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="23736134-3ea8-4d8a-a4f5-50cb1c799bce">
	  <name>Oxleas NHS Foundation Trust</name>
	  <address>Pinewood House
Pinewood PLACE</address>
	  <city>Dartford</city>
	  <state/>
	  <country>England</country>
	  <zip>DA2 7WG</zip>
	  <rtsId>RPG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="55dcee17-d7a1-4589-a557-721d599783d3">
	  <name>Birmingham and Solihull Mental Health NHS Foundation Trust</name>
	  <address>The Uffculme Centre
52 Queensbridge Road
Moseley</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B13 8QY</zip>
	  <rtsId>RXT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="c1b21257-2dfe-41b7-9c09-bfa393b9bb91">
	  <name>North London NHS Foundation Trust</name>
	  <address>4th Floor, East Wing
St. Pancras Hospital
4 St. Pancras Way</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 0PE</zip>
	  <rtsId>G6V2S@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="968635bc-2d1c-4ab8-8a86-8e0345ba7a57">
	  <name>East London NHS Foundation Trust</name>
	  <address>Robert Dolan House
9 Alie Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>E1 8DE</zip>
	  <rtsId>RWK@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="f49506d8-e907-4855-bd69-575acc5788cb">
	  <name>NHS Lanarkshire</name>
	  <address>Kirklands, Fallside Road</address>
	  <city>Bothwell</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>G71 8BB</zip>
	  <rtsId>SL999@2.16.840.1.113883.2.1.3.8.2.16.1</rtsId>
	</trialCentre>
	<trialCentre id="a938e2be-0af1-497f-b528-0bd00f9dac32">
	  <name>Greater Manchester Mental Health NHS Foundation Trust</name>
	  <address>Prestwich Hospital
Bury New Road
Prestwich</address>
	  <city>Manchester</city>
	  <state/>
	  <country>England</country>
	  <zip>M25 3BL</zip>
	  <rtsId>RXV@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1.  Aged 18 or older  
2. Resident of a temporary accommodation
3. One or more of the below:
3.1. Mental health problem  
3.2. Substance (includes alcohol) use  
3.3. History of criminal justice encounter 
3.4. Equal to or longer than 6 months in one stay or repeat stay in temporary accommodations</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="125.0">125 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>426</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>Residents lacking mental capacity to consent</exclusion>
      <recruitmentStart>2027-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Homelessness, mental health, substance use disorders, multiple complex needs</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>REACH will be delivered by a care team consisting of a mental health practitioner who will be recruited from a local NHS Trust alongside a named care navigator from a local voluntary, charity, social enterprise (VCSE)/NHS Trust. The intervention team will use a strengths-based approach to engage with participants and agree shared goals. The care team will look after approximately 18-22 participants, meeting them weekly/as required. The King's Clinical Trials Unit (KCTU) will provide a bespoke web-based randomisation system to allocate participants to the intervention in addition to usual care or usual care alone. 

The intervention will be highly structured. In addition to Usual care, REACH will include:
1. Holistic health and care needs assessment (procedures tested in our pilot study); mental health (anxiety, depression, psychosis, PTSD assessment); substance use disorders, physical health (e.g. blood pressure, BMI, random glucose, referral for a 12-point ECG if risk factors identified, blood borne viruses, dyspnoea assessment; skin integrity/pressure ulcers, foot assessment). 
2. Facilitating access to national health screening programmes (e.g. &gt; 40 health checks), flu/COVID-19 vaccination, Hepatitis B, shingles (if eligible), pharmacy smoking cessation. 
3. Intervention staff will offer immediate treatment (within areas of expertise) or arrange referrals and accompany participants to appointments for the provision of evidence-based therapies (e.g. CBT), support medication optimisation and adherence, expedited (often the same day) referral to local Drug &amp; Alcohol treatment providers, facilitating care pathways for traumatic brain injuries.
4. Social-needs assessment and support (housing, welfare benefits assessment, bank account, criminal justice, clothing, access to nutritious meals).
5. Harm reduction (e.g. naloxone training and supply, support for safe substance consumption including needle exchange and foil provision, sexual health advice, condom provision and referral).
6. Attendance at the multi-agency weekly meeting and formulation of multiagency care plan with action points for each agency.
7. Social prescribing, facilitation of access to free bus passes or provision (up to £150 per person for participants non-eligible through other means); liaison with local organisations for available opportunities to address isolation/boredom, facilitate participation in sustainable employment training skills that are available locally (e.g. IT skills), green prescribing initiatives (gardening, arts/crafts) and promote wellbeing.
8. Step-up accommodation/street outreach: intervention will continue if participant transitions to another setting.
9. Support for family reconnections if desirable by study participants.

Initial consultations will be held in temporary accommodation consultation/safe areas. Care team will also utilise nearby community centres, local GP practices, VCSE hubs and soup kitchens as agreeable by the participants and venue providers. Uptake of REACH will be maximised, and dropout minimised, through proactive follow up, door knocking and assertive outreach where participants move on to other accommodation providers or streets. Intervention will last for up to 12 months to allow sufficient time for the REACH team to develop trust/rapport with participants, provide treatment and sustain recovery. Throughout the intervention the patient will continue to engage with mainstream care. When the intervention period finishes, the participant will return to receiving usual care alone.

Usual care: Participants will receive care as usual from the temporary accommodation staff and any existing support from external providers. In addition, a leaflet will be provided by the recruiting researcher describing health and care support available for people experiencing homelessness (PEH) in the area.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>c279992d-3f54-4e95-a73a-4d05a58673be</funderId>
      <contactId>021c2c8c-9ffc-4e66-9879-6c96117c1e67</contactId>
      <contactId>722ea6c6-43af-49e0-a698-e345ea7b1cfd</contactId>
      <sponsorId>c2ff360e-a426-4cd9-8a6a-677052a2f676</sponsorId>
      <sponsorId>c3aab693-8709-4976-8449-5dd9786a97eb</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="021c2c8c-9ffc-4e66-9879-6c96117c1e67">
    <title>Prof</title>
    <forename>Vibhu</forename>
    <surname>Paudyal</surname>
    <orcid>https://orcid.org/0009-0001-3887-8893</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>King's College London</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SE1 8WA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7836 5454</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vibhu.paudyal@kcl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="722ea6c6-43af-49e0-a698-e345ea7b1cfd">
    <title>Ms</title>
    <forename>Lena</forename>
    <surname>Johansson</surname>
    <orcid>https://orcid.org/0000-0002-4473-1134</orcid>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>King's Clinical Trials Unit, 16 De Crespigny Park</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SE5 8AF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">44 (0)20 7848 0532</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">reachtrial@kcl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="c2ff360e-a426-4cd9-8a6a-677052a2f676">
    <organisation>King's College London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/0220mzb33</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <sponsor id="c3aab693-8709-4976-8449-5dd9786a97eb">
    <organisation>South London and Maudsley NHS Foundation Trust</organisation>
    <sponsorType/>
    <rorId>https://ror.org/015803449</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="c279992d-3f54-4e95-a73a-4d05a58673be">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-10-09T15:17:10.994730727Z" version="13" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN18246561" publicIdentifierDateAssigned="2026-10-12T14:59:46.962647Z">
    <isrctn dateAssigned="2026-10-12T14:59:46.962647Z">18246561</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Mindfulness skills training for children</title>
      <scientificTitle>Supporting the mental health of children through stix innovation: a feasibility trial</scientificTitle>
      <acronym>STIX</acronym>
      <studyHypothesis>1. To determine feasibility of recruitment and willingness to be randomised to Stix (intervention) or standard care (control) condition
2. To estimate retention and follow-up rate, and acceptability of outcome data collection
3. To identify characteristics (sociodemographic and clinical) that may prevent children from being able to engage with a full-scale RCT
4. To determine user and parental acceptability of Stix, and the level of engagement with Stix training modules
5. To determine practicality of using Stix in a home setting (the level of parental/caregiver support that will be required)
6. To determine contamination rate in the control arm
7. To determine suitability of instruments to measure the effects of the intervention (outcomes) in a definitive trial</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Mental health difficulties are becoming increasingly common among children, and many children experience delays in accessing support. Mindfulness could help children develop skills to manage stress, emotions and everyday challenges, but existing mindfulness programmes are not always engaging or suitable for younger children. Stix Mindfulness is a screen-free mindfulness programme delivered through handheld electronic devices that use sounds, vibrations and lights to guide children through mindfulness activities. The aim of this study is to examine whether Stix Mindfulness is acceptable to children and their families, whether children are willing to use it, and whether the study procedures are feasible for a future larger trial evaluating its effectiveness.

Who can participate?
Children aged between 8 and 10 years (at the point of consent) who need support for their mental health and wellbeing, but who are not currently receiving support from an NHS mental health professional or are on a waiting list to receive such support, will be invited to participate. Parents or caregivers of eligible children and relevant school staff may also take part in some aspects of the study, where relevant.

What does the study involve?
Each child will participate for around 13 weeks, including baseline assessment, a 6-week intervention or standard care period, and a further 6-week follow-up period.
Following parental consent and child assent, children will complete baseline questionnaires about their mental health, mindfulness skills, and sleep. Participants will then be randomly allocated to either receive Stix Mindfulness training (intervention group) or no intervention (standard care control group).
Children practicing the Stix Mindfulness training will receive a pair of Stix devices and will be encouraged to practice mindfulness activities at home for 6 weeks, for about 10 minutes a day, with support from parents or caregivers as needed. Children continuing with standard care will continue with their usual support, but will not receive the Stix Mindfulness training immediately - they will be offered the same 6 weeks Stix Mindfulness training after they finish being part of the control group for the study. All participants will complete follow-up assessments at 6 and 12 weeks after randomisation. 
Parents/caregivers will be asked to provide information about the child’s behaviour, specifically their attention, hyperactivity, impulsivity as well as social skills, attention to details, communication and imagination at study entry,  and both parents/caregivers and teachers will be asked about the child's engagement at home and school at baseline, 6 and 12 weeks. Some children, parents/caregivers and school staff may be invited to participate in interviews, lasting about 1 hour, to share their experiences of the intervention and study procedures.

What are the possible benefits and risks of participating?
The training involves a range of fun activities to improve children’s mindful awareness of their breath, body, feelings, and thoughts. The training is both fun to take part in, and participants may benefit from learning mindfulness skills that could help them manage everyday stress, improve emotional wellbeing, develop coping strategies, improve their personal relationships, and enhance their overall wellbeing. You may also feel intrigued and decide to further read into the topic of mindfulness and increase your knowledge base around this.  
Stix has already been tested in children without any safety issue or risk at St Mary’s CofE Primary School in Kent, Hewens Primary School in Hayes, as well as by Youth Resilience UK CIC. Some participants may find mindfulness activities or questions about their mental health upsetting. Participants can withdraw from the study at any time without giving a reason. If a child is identified as experiencing severe anxiety or depression during assessment, the research team will follow an agreed safeguarding pathway and inform appropriate services through procedures agreed with participating schools and the ethics committee.

Where is the study run from?
The study is sponsored and coordinated by Brunel University of London in collaboration with the University of Surrey, University of Birmingham, Health Innovation East, and NIHR ARC East of England, and will be conducted through participating schools in and around London. Assessments may take place at school or at home, according to participant preference.

When is the study starting and how long is it expected to run for?
October 2026 to August 2028

Who is funding the study?
The study is funded by the National Institute for Health and Care Research (NIHR209767) (UK)

Who is the main contact?
1. Dr Krupa Vakani, Research Fellow, krupa.vakani3@brunel.ac.uk
2. Prof. Veena Kumari, veena.kumari@brunel.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="da175f59-f30d-42f2-880b-b4c7223a405f">
	  <variable>Recruitment feasibility</variable>
	  <method>the recruitment rate (% of eligible participants providing parental consent and child assent)</method>
	  <timepoints>the end of the recruitment period</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="651f8ec7-41db-4682-aa77-eda85a728240">
	  <variable>Intervention adherence</variable>
	  <method>Stix usage data collected via the Stix application and device records</method>
	  <timepoints>6 weeks (T1)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="be6722b8-c615-4b98-a489-16b0e16932ac">
	  <variable>Acceptability of the Stix Mindfulness intervention</variable>
	  <method>the Stix acceptability questionnaire using a five-point Likert scale</method>
	  <timepoints>6 weeks (T1)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="43ff349c-861a-4b4b-9e2e-1f36928e1461">
	  <variable>Participant retention rate</variable>
	  <method>the proportion of participants completing all 6 weeks of activities and follow-up assessments</method>
	  <timepoints>12 weeks (T2)</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="50f75c82-f330-4de7-9a8a-d4c4ff2dfeef" approvalStatus="approved" statusDate="2026-08-03T00:00:00.000Z">
	  <committeeName>College of Health, Medicine and Life Sciences Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>Brunel University of London, Kingston Lane, Uxbridge</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>UB3 3PH</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>39784-A-Jul/2026-55423-2</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18246561</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NIHR: 209767</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="2955941c-4e12-4a3c-8188-ebd06e1629db" numberType="nihr" canonicalSecondaryNumber="NIHR209767">209767</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Uncontrolled</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Prevention</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2028-08-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="093a00de-3ec3-4d7c-98f4-eff20313ff15">
	  <name>Brunel University London</name>
	  <address>Kingston Lane</address>
	  <city>Uxbridge</city>
	  <state/>
	  <country>England</country>
	  <zip>UB8 3PH</zip>
	  <rtsId>10000961@2.16.840.1.113883.2.1.3.8.2.9.1</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>Children aged between 8-10 years who:
1. Have mild-to-moderate anxiety and/or depression but are not receiving, or are currently on a waiting list for receiving help from mental health professional
2. Are able to provide assent, with parental/guardian consent</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="years" value="8.0">8 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="10.0">10 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Unable to hold the Stix device and therefore practice Stix Mindfulness training due to a physical disability and/or impairment
2. Participant has clinical levels of depression and/or anxiety, identified during the initial assessment through the relevant psychometric test, due to wellbeing concerns and immediate need for clinical interventions</exclusion>
      <recruitmentStart>2026-10-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Children’s  mental health and wellbeing</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After receiving both parental consent and child assent, participants will be screened for anxiety and depression using the Revised Child Anxiety and Depression Scale-Short Version (RCADS-25). Those meeting the study inclusion and exclusion criteria will then be randomised on a 1:1 basis by a team member (who is not involved in study assessments) to receive Stix Mindfulness training (intervention group) or no intervention  (standard care control group), stratified by participant’s sex.

Participants allocated to the intervention group will receive 6 weeks of Stix Mindfulness training using handheld, screen-free, electronic devices (Stix remotes) that deliver mindfulness exercises through audio, vibration and light-based feedback. Participants will be encouraged to practice at home for at least 10 minutes per day (approximately three activities daily) over the 6-week intervention period, with parental support as required (i.e., for charging devices etc). 

Participants allocated to the standard care group will continue routine as usual, and will not receive 6 weeks of Stix Mindfulness training at the same time as the intervention group. 

All participants will complete outcome assessments at baseline, 6 and 12 weeks, including questionnaires on anxiety, depression (RCADS-25), mindfulness (Mindful Attention Awareness Scale for Children), and a subjective sleep quality question. Parents/caregivers will be asked to provide information about the child’s behaviour, specifically their attention, hyperactivity, impulsivity (using the ADHD Rating Scale-IV: Home Version) as well as social skills, attention to details, communication and imagination (using The Autism Spectrum Quotient – Child’s Version) at study entry,  and both parents/caregivers and teachers will be asked about the child's engagement at home and school at baseline, 6 and 12 weeks. 

A subgroup of children, parents/caregivers and school staff may also take part in semi-structured interviews, lasting up to 1 hour, to explore the acceptability and feasibility of the Stix Mindfulness intervention and overall study procedures.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study will be stored in publicly available repositories (brunel.figshare.com). Only de-identified (without participants’ names and any other personal information) quantitative data will be stored in publicly available repositories. The quantitative data will be available within 4 months of the end of the study and will be preserved for the long term. Qualitative data will not be stored in repositories due to the potential of compromising confidentiality. Consents from participants will be sought for storing the de-identified data collected in this study in the repositories. Only the data that will have participants’ consent will be stored in the repositories.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Stored in publicly available repository</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7830c5c8-aa9c-4e40-b9ae-2555075c58c8" outputType="trialwebsite" artefactType="ExternalLink" dateCreated="" dateUploaded="2026-10-09T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<externalLink url="https://www.brunel.ac.uk/research/projects/supporting-the-mental-health-of-children-through-stix-innovation"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>412ec4bf-1167-43ea-87ff-4f27cb035089</funderId>
      <contactId>e04651a5-517f-4e8a-bfe8-0d1379ea4440</contactId>
      <contactId>4ae87f4b-f838-4dae-a472-6311cd688398</contactId>
      <sponsorId>f22f4add-5b60-4302-a302-b98f74414ec3</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="e04651a5-517f-4e8a-bfe8-0d1379ea4440">
    <title>Dr</title>
    <forename>Krupa</forename>
    <surname>Vakani</surname>
    <orcid>https://orcid.org/0000-0001-8625-1895</orcid>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Brunel University of London, Kingston Lane, Uxbridge</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>UB3 3PH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1895 274 000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krupa.vakani3@brunel.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="4ae87f4b-f838-4dae-a472-6311cd688398">
    <title>Prof</title>
    <forename>Veena</forename>
    <surname>Kumari</surname>
    <orcid>https://orcid.org/0000-0002-9635-5505</orcid>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Brunel University of London, Kingston Lane, Uxbridge</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>UB3 3PH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1895 274 000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">veena.kumari@brunel.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="f22f4add-5b60-4302-a302-b98f74414ec3">
    <organisation>Brunel University of London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/00dn4t376</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="412ec4bf-1167-43ea-87ff-4f27cb035089">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-17T16:10:15.735669611Z" version="12" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN91960330" publicIdentifierDateAssigned="2026-10-02T09:22:36.330831Z">
    <isrctn dateAssigned="2026-10-02T09:22:36.330831Z">91960330</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Weight management before surgery</title>
      <scientificTitle>A randomised controlled trial to examine the feasibility of a weight management programme prior to surgery with embedded qualitative study</scientificTitle>
      <acronym>PreWel</acronym>
      <studyHypothesis>The primary objective is to examine the feasibility and acceptability of referring participants and the participation in a weight management programme to improve post-operative outcomes. 

The trial also aims to assess:
1. Weight change from start of programme to pre-surgery and from the start of programme to post-surgery
2. Unexpected, serious adverse events during the weight management programme and post-surgery (up to 90 days)

To see if we can collect data for a future trial: 
1. Complications from surgery
2. Health care resource use
3. Health-related quality of life

To examine the processes involved for the feasibility trial and allow refinement for a future trial we will: 
1. Examine engagement with weight management
2. Examine heterogeneity between surgical operations
3. Examine contamination with the comparator group
4. Describe who takes part in the trial to assess equality, diversity and inclusion
5. Examine methods to collect postoperative data</studyHypothesis>
      <plainEnglishSummary>Background and study aims
About one-third of people on NHS surgical waiting lists live with obesity. Living with obesity prior to surgery may increase the risk of surgical complications, such as wound infections, heart problems, and longer hospital stays. Although effective weight management programmes exist, they are not routinely offered to patients while they wait for surgery. 
The PRE Weight Loss (PRE-WEL) study aims to find out whether it is practical and acceptable to offer free weight management programmes to patients preparing for surgery. The study will also measure weight changes, hospital stay length, surgical complications, quality of life, and healthcare resource use to help design a future larger-scale trial. 

Who can participate?
Patients aged 18 years or older with Body Mass Index (BMI) 30 kg/m² or higher, who are referred for hip or knee joint replacement, laparoscopic cholecystectomy (gallbladder removal), hysterectomy, or coronary artery bypass graft and/or valve surgery (between 1 and 6 months before their scheduled operation date)

What does the study involve?
Participants will be randomly placed into one of two groups: 
1. The weight management group are offered a choice of free weight management programmes) to access for 1 to 6 months before surgery. 
2. The booklet group are given an NHS weight management information booklet. 
Participants will complete short questionnaires and send a photograph of their weight reading from home scales at the start, shortly before surgery, and 90 days after surgery. Surgical details and post-surgery recovery information will also be collected from hospital and GP records. Participants can optionally choose to take part in interviews or keep voice/paper diaries sharing their experiences. 

What are the possible benefits and risks of participating?
Participants receive free access to a structured weight loss programme or booklet, which may help them lose weight before surgery. All participants contribute to research aimed at improving pre-operative NHS care. Participants receive a £20 voucher each time for completing follow-up assessments or qualitative sub-studies. 
The overall risk is low and no higher than standard NHS care. Weight management programmes are non-invasive. 

Where is the study run from?
The study is managed by Loughborough University (Centre for Lifestyle Medicine and Behaviour) in partnership with the Leicester Clinical Trials Unit (LCTU) (UK)

When is the study starting and how long is it expected to run for?
November 2026 to August 2029

Who is funding the study?
National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?
Dr Claire D. Madigan, prewel@mailbox.lboro.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="ff2982d9-2cc9-4633-bd51-7edd03982a9c">
	  <variable>The feasibility and acceptability of referral and participation in a weight management programme before surgery,</variable>
	  <method>the number of participants randomised after a 12-month recruitment period; engagement with the intervention; retention rate: the number of participants</method>
	  <timepoints>follow-up (pre-surgery and 90-days post-surgery) as a proportion of participants randomised; embedded think aloud study and qualitative interviews with participants will examine the acceptability of referral and participation in weight management programmes</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome>1. Change in weight measured in kg from baseline to  pre-surgery and baseline to 90 days post-surgery
2. Number of serious adverse events occurring prior to surgery as a proportion of participants randomised
3. Number of serious adverse events occurring during surgery and up to 90-days post-surgery as a proportion of participants randomised
4. The proportion of participants with no specified complications related to surgery, hospitalization or mortality from date of surgery up to 90 days post-surgery
5. The proportion of participants that are readmitted to hospital, have a re-operation or mortality within 90 days post-surgery
6. Length of stay (LOS), defined as the time in days between admission for surgery and discharge from surgery
7. Surgery duration, measured in minutes as recorded in hospital notes
8. The number of participants with complete data as a proportion of participants randomised when quality of life is measured using EQ-5D-5L at baseline, pre-surgery and 90-days post-surgery
9. Engagement data collected from the weight management programmes
10. The length of access to the weight management programme, defined as the time between first attendance and their surgery
11. Heterogeneity between surgical operations measured using the means (SD) and proportions by surgical operation of the weight change data and the postoperative complications
12. Whether weight management interventions are delivered as planned and patient’s experiences of the intervention, measured using qualitative interviews and think aloud sub-study during the weight management programme
13. Comparator group contamination measured using:
13.1. Proportion of participants randomised to the comparator arm whose weight pre-operatively remains within 2 kg of baseline weight
13.2. Proportion of the comparator that actively managed their weight pre-operatively, defined as answering yes to the question about actively managing their weight and answered yes to options other than “I have been following the plan” 
14. Number and proportion (of randomised) participants by age, sex, ethnicity, index of multiple deprivation, comorbidities, malnutrition status (as measured using PS-SGA short form) and long-term health condition
15. The number of participants with data collected from hospital records, GP data and patient-reported data as a proportion of participants randomised, reported separately for each method</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="b0b45e87-4602-4f4d-b60a-4ea9835d57b9" approvalStatus="approved" statusDate="2026-09-29T00:00:00.000Z">
	  <committeeName>London - Bromley Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/LO/0622</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91960330</doi>
      <eudraCTNumber/>
      <irasNumber>371974</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 74081, NIHR: 303187</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="86d9ccc2-8265-4cbe-a30f-85af9ab3a562" numberType="iras" canonicalSecondaryNumber="IRAS371974">371974</secondaryNumber>
	<secondaryNumber id="7c04078d-6f3d-4a66-8571-c4767b9ad6ad" numberType="cpms" canonicalSecondaryNumber="CPMS74081">74081</secondaryNumber>
	<secondaryNumber id="f891358e-79e0-4c44-b68e-ec957ef9323b" numberType="nihr" canonicalSecondaryNumber="NIHR303187">303187</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2029-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f34be975-7c05-4c06-afa5-a2f8a775bc3c">
	  <name>Loughborough University</name>
	  <address>Epinal Way</address>
	  <city>Loughborough</city>
	  <state/>
	  <country>England</country>
	  <zip>LE11 3TU</zip>
	  <rtsId>10004113@2.16.840.1.113883.2.1.3.8.2.9.1</rtsId>
	</trialCentre>
	<trialCentre id="13d174b3-0153-4868-bb83-5e81ba29922e">
	  <name>University of Leicester</name>
	  <address>Department of Cardiovascular Sciences
University of Leicester
Glenfield Hospital</address>
	  <city>Leicester</city>
	  <state/>
	  <country>England</country>
	  <zip>LE3 9QP</zip>
	</trialCentre>
	<trialCentre id="d67a95c8-4b1c-4f90-9469-1b1841236531">
	  <name>University Hospitals Bristol and Weston NHS Foundation Trust</name>
	  <address>Marlborough Street</address>
	  <city>Bristol</city>
	  <state/>
	  <country>England</country>
	  <zip>BS1 3NU</zip>
	</trialCentre>
	<trialCentre id="c550f1b6-f904-4b39-a12b-b0b1db1988ba">
	  <name>North Bristol NHS Trust</name>
	  <address>Southmead Hospital
Southmead Road
Westbury-On-Trym</address>
	  <city>Bristol</city>
	  <state/>
	  <country>England</country>
	  <zip>BS10 5NB</zip>
	</trialCentre>
	<trialCentre id="69ec40c3-dc63-467c-be1a-7717c10b8765">
	  <name>University Hospitals of Leicester NHS Trust</name>
	  <address>Leicester Royal Infirmary
Infirmary Square</address>
	  <city>Leicester</city>
	  <state/>
	  <country>England</country>
	  <zip>LE1 5WW</zip>
	  <rtsId>RWE@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="2ffafc83-96aa-4edf-9507-e19fa1cffc13">
	  <name>University Hospitals Birmingham NHS Foundation Trust</name>
	  <address>Queen Elizabeth Hospital
Mindelsohn Way
Edgbaston</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B15 2GW</zip>
	  <rtsId>RRK@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="9d6ab04c-277d-443a-91ba-d801021a22a2">
	  <name>University Hospitals of Derby and Burton NHS Foundation Trust</name>
	  <address>Royal Derby Hospital
Uttoxeter Road</address>
	  <city>Derby</city>
	  <state/>
	  <country>England</country>
	  <zip>DE22 3NE</zip>
	  <rtsId>RTG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="44c528b6-e9cb-4008-921d-e90b9b185a00">
	  <name>South Tees Hospitals NHS Foundation Trust</name>
	  <address>James Cook University Hospital
Marton Road</address>
	  <city>Middlesbrough</city>
	  <state/>
	  <country>England</country>
	  <zip>TS4 3BW</zip>
	  <rtsId>RTR@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Aged &gt;=18 years
2. Referred for hip/knee replacement, laparoscopic cholecystectomy, hysterectomy or coronary artery bypass graft and/ or valve surgery
3. Body mass index (BMI) &gt;=30 kg/m2</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Greater than 6 months to operation date or less than one month before operation date
2. Urgent/emergency or surgery listed outside of the inclusion criteria
3. Currently/recently enrolled in a weight management programme or lost &gt;3 kg of weight in the last 3 months
4. Women known to be pregnant of breastfeeding
5. History of eating disorders within the last 10 years
6. Any other significant disease or disorder which, in the opinion of the investigator or healthcare team, may put the participant at risk because of participation in the trial (e.g., serious mental health concerns)</exclusion>
      <recruitmentStart>2027-01-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hip/knee joint replacement, laparoscopic cholecystectomy, hysterectomy, or coronary artery bypass graft/valve surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants will be randomised stratified by surgical speciality (hip/knee joint replacement, laparoscopic cholecystectomy, hysterectomy or coronary artery bypass graft and/ or valve surgery) using random block sizes. Participants will be randomly assigned (1:1) to either:
1. Intervention arm: free referral to a weight management programme of their choice for up to 6 months before surgery.
2. Control arm: delivery of a NHS weight management booklet. 

Data will be collected at baseline, 1 week pre-surgery, and 90 days post-surgery via electronic questionnaires and participant-submitted weight photographs.

Optional embedded qualitative sub-studies (interviews and WhatsApp "think aloud" voice notes) will gather real-time data on participant experiences. Progression to a full-scale trial will be guided by definitive traffic-light criteria tracking recruitment and retention rates.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Data sharing statement to be made available at a later date</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>9da547d7-3ed5-4621-b23c-a9cd4a4966d2</funderId>
      <contactId>2c3f3ad7-da40-4f6c-b1c0-356fbb899599</contactId>
      <contactId>34d7a2d8-c1c0-4c63-b4bd-ee68a8d86ae9</contactId>
      <sponsorId>fac32cb1-3489-4ba9-bda8-c02c215fe374</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="2c3f3ad7-da40-4f6c-b1c0-356fbb899599">
    <title>Dr</title>
    <forename>Claire</forename>
    <surname>Madigan</surname>
    <orcid>https://orcid.org/0000-0002-6782-0017</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Sport Exercise and Health Sciences, Loughborough University, Epinal Way</address>
      <city>Loughborough</city>
      <state/>
      <country>United Kingdom</country>
      <zip>LE11 3TU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1509223008</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.madigan@lboro.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="34d7a2d8-c1c0-4c63-b4bd-ee68a8d86ae9">
    <title>Miss</title>
    <forename>Charlotte</forename>
    <surname>Doleman</surname>
    <orcid/>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Sport Exercise and Health Sciences, Loughborough University, Epinal Way</address>
      <city>Loughborough</city>
      <state/>
      <country>United Kingdom</country>
      <zip>LE11 3TU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1509226501</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">C.L.Doleman1@lboro.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="fac32cb1-3489-4ba9-bda8-c02c215fe374">
    <organisation>Loughborough University</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/04vg4w365</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="9da547d7-3ed5-4621-b23c-a9cd4a4966d2">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-09-14T12:22:37.426648985Z" version="16" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN16804705" publicIdentifierDateAssigned="2026-09-14T11:03:39.376808Z">
    <isrctn dateAssigned="2026-09-14T11:03:39.376808Z">16804705</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparing indoor and outdoor group psychological therapy for older adults in NHS hospitals</title>
      <scientificTitle>Indoor Versus OutdooR group psychological therapy for older adults in NHS inpatient settings; a feasibility study of a pragmatic, cluster randomized controlled trial (RCT)</scientificTitle>
      <acronym>IVOR</acronym>
      <studyHypothesis>This is a small-scale pilot study designed to assess whether a larger trial would be feasible. The study compares indoor and outdoor group psychological therapy for older adults receiving NHS inpatient care. It will assess how practical and acceptable it is to deliver the two approaches and whether the study procedures are manageable. The findings will help determine whether and how a larger trial could be conducted in the future.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
People who spend time outdoors may experience benefits to their mental health and wellbeing, such as reduced stress and improved mood. However, psychological therapy in NHS hospitals is usually delivered indoors. There is some evidence that providing psychological therapy outdoors may help people feel better and become more engaged with therapy, but there is not yet enough research to know whether this is practical and beneficial for older adults receiving care in NHS hospitals.
This study will compare group psychological therapy delivered indoors with the same type of therapy delivered outdoors for older adults staying in NHS hospital wards. The study will help us understand whether outdoor psychological therapy is practical and acceptable for patients and staff. It will also help us decide whether a larger study should be carried out in the future.

Who can participate?
People who are currently receiving care on dementia and frailty inpatient wards at Birmingham and Solihull Mental Health NHS Foundation Trust may be able to take part. Participants will need to have been invited to attend group psychological therapy and be able to give informed consent to take part in the research.  Staff involved in delivering or supporting the therapy may also be invited to provide their views about delivering psychological therapy outdoors.

What does the study involve?
Participants who agree to take part will attend group psychological therapy as part of their usual care. The therapy will be delivered either indoors or outdoors.
The ward will be assigned to either the indoor or outdoor therapy group, meaning that participants on the same ward will receive the same type of therapy. Participants will not individually choose whether their therapy is delivered indoors or outdoors.
Participants will be asked to complete questionnaires about their wellbeing and their experience of the therapy. These questionnaires will be completed before the therapy, after the therapy, and again approximately 3 months later.
The study will also collect information about how many people agree to take part, whether participants attend the therapy sessions, and whether the therapy can be delivered as planned. Staff will be asked about their experience of delivering therapy outdoors.

What are the possible benefits and risks of participating?
Benefits: This study will help us to consider the feasibility of delivering outdoor psychological therapy. Whilst there may be no immediate benefits to participants, the aim is to improve care for future patients on the ward.
Risks: Some of the disadvantages of taking part are that participants may find it time consuming to complete the questionnaires and that they will not be able to choose where the group psychological therapy is conducted (indoors or outdoors) as it is randomly allocated. For participants who receive outdoor group psychological therapy, they may be exposed to adverse weather conditions, they may find it more difficult to walk to the venue, and there may be less privacy. Taking part is voluntary, and participants can choose not to take part or withdraw from the research without this affecting their usual care.

Where is the study run from?
The study is sponsored by the University of Birmingham and is delivered at Birmingham and Solihull Mental Health NHS Foundation Trust. It will take place on dementia and frailty inpatient wards within the Trust, including the Juniper Centre and Reservoir Court.

When is the study starting and how long is it expected to run for?
The study started recruitment in May 2026 and the study will end in January 2027. 

Who is funding the study?
Investigator initiated and funded.

Who is the main contact?
Dr Stephanie Howarth
Principal Investigator s.l.howarth@bham.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="1e8b43c3-3734-45ff-a4cb-655f9e6c29f1">
	  <variable>Recruitment rates</variable>
	  <method>Number and proportion of eligible participants recruited to the study, measured against the target recruitment of 16–24 participants. Recruitment rate will be calculated as the number of participants consenting to take part divided by the number of eligible participants approached/invited, expressed as a percentage. The number recruited per week will also be recorded</method>
	  <timepoints>from the start of participant recruitment until the end of the recruitment period (approximately 16 weeks).</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="5d5ed5f3-cbe0-4f17-8d84-8a3d97a17ad1">
	  <variable>Acceptability of intervention</variable>
	  <method>Acceptability of Intervention Measure</method>
	  <timepoints>post-intervention</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="245d2185-e4c0-4b26-ad76-f7147ba3a4f3" approvalStatus="approved" statusDate="2026-02-19T00:00:00.000Z">
	  <committeeName>Seasonal REC</committeeName>
	  <contactDetails>
	    <address>2 Redman Place
Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/LO/0064</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16804705</doi>
      <eudraCTNumber/>
      <irasNumber>362658</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber/>
      <secondaryNumbers>
	<secondaryNumber id="ce42fc5b-e421-47a3-b34f-f8b92ac1d0c5" numberType="iras" canonicalSecondaryNumber="IRAS362658">362658</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	  <purpose>Feasibility of outdoor group psychological therapy</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2027-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3d580b9c-82d3-4497-b7d1-10532091045d">
	  <name>Birmingham and Solihull Mental Health NHS Foundation Trust</name>
	  <address>The Uffculme Centre
52 Queensbridge Road
Moseley</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B13 8QY</zip>
	  <rtsId>RXT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>Participants (service users) will be eligible to take part in the study if:
1.	They are aged 18 years or above
2.	They are currently receiving care from inpatient services at the Juniper Centre or Reservoir Court, Birmingham and Solihull NHS Foundation Trust
3.	They are due to take part in a therapy group, such as Stressbusters
4.	They have read the Participant Information Sheet and had the opportunity to speak to a researcher and ask any questions they may have about the study
5.	There are no concerns about their capacity to provide informed consent to take part in the study
6.	They provide informed consent by completing the Informed Consent Form

Participants (staff) will be eligible to take part in the study if:
1.	They are currently working in inpatient settings at the Juniper Centre or Reservoir Court, Birmingham and Solihull NHS Foundation Trust
2.	They facilitate or co-facilitate groups, such as Stressbusters
3.	They have read the Participant Information Sheet and had the opportunity to speak to a researcher and ask any questions they may have about the study
4.	They provide informed consent by completing the Informed Consent Form</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="120.0">120 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>Participants (service users) will be excluded from the study if:
1.	They are not currently receiving inpatient care from the Juniper Centre or Reservoir Court, Birmingham and Solihull NHS Foundation Trust
2.	They are not due to take part in a therapy group, such as Stressbusters
3.	They are unable to understand the Participant Information Sheet or do not have the opportunity to speak with a researcher about the study
4.	There are concerns about their capacity to provide informed consent to take part in the study
5.	They do not provide informed consent by completing the Informed Consent Form

Participants (staff) will be excluded from the study if:
1.	They are not currently working in inpatient settings at the Juniper Centre or Reservoir Court
2.	They do not facilitate or co-facilitate groups such as Stressbusters
3.	They are unable to understand the Participant Information Sheet or do not have the opportunity to speak with a researcher about the study
4.	They do not provide informed consent by completing the Informed Consent Form</exclusion>
      <recruitmentStart>2026-05-28T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2026-09-17T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Psychological therapy for psychological distress in adults and older adults receiving inpatient mental health care for a range of mental health conditions and/or dementia</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention arm – outdoor Stressbusters group: Older adult inpatients due to attend the routinely offered Stressbusters therapy group will receive five weekly, one-hour group psychological therapy sessions delivered in an outdoor space on the ward. Each session focuses on one of the five senses (sight, hearing, taste, touch and smell) and provides strategies to reduce stress, using activities such as smelling lavender, looking at calming images or listening to uplifting music.

Comparator arm – indoor Stressbusters group: Older adult inpatients will receive the same five weekly, one-hour Stressbusters group sessions, but delivered indoors. The content, frequency and duration of the therapy will be the same as in the outdoor arm, with the setting being the main difference between the two groups.

Participants will be grouped according to the ward on which they are receiving inpatient care. Each ward-based group (cluster) will be randomly allocated to either the indoor or outdoor intervention. The study aims to recruit 16–24 participants across the four wards.

Participants will complete questionnaires before and after the five-week intervention and at three-month follow-up. Brief feedback will also be collected after each session. Staff delivering the groups will complete questionnaires about their experience of delivering the therapy in the allocated setting. The study will assess the feasibility of recruitment, attendance and outcome measurement, as well as the acceptability and practicality of delivering Stressbusters indoors or outdoors. 

Randomisation
Participants will be randomised by cluster according to the ward on which they are receiving inpatient care. Each cluster will comprise between 1 and 8 participants and will be randomised in a 1:1 ratio to receive the Stressbusters psychological therapy either indoors or outdoors. Block randomisation will be used to allocate clusters to the two study arms.

An independent researcher, who is not involved in delivering the therapy, will conduct the randomisation using an Excel spreadsheet. Following randomisation, the researcher will inform the relevant therapy staff and service user participants whether the upcoming Stressbusters group will be delivered indoors or outdoors. The group will then be delivered in the allocated setting.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f720905e-7908-4844-a31a-c23b12682db2" outputType="pis" artefactType="LocalFile" dateCreated="2025-08-01T00:00:00.000Z" dateUploaded="2026-09-07T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="45394494-5e85-478f-8d1c-39937f5b12cd" originalFilename="50104 Participant Information Sheet (Service User) v1.0 01Aug2025.pdf" downloadFilename="50104 Participant Information Sheet (Service User) v1.0 01Aug2025.pdf" version="1.0" mimeType="application/pdf" length="146239" md5sum="3af1c3a85d45ec9bb5612e67209e5c80"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="ccf75af2-6cad-489c-80ed-9c670b857d5d" outputType="protocolfile" artefactType="LocalFile" dateCreated="2025-08-01T00:00:00.000Z" dateUploaded="2026-09-07T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="b55bee6e-57bc-4e53-a6be-a2e75c5c94b5" originalFilename="50104 Protocol v1.0 01Aug2025.pdf" downloadFilename="50104 Protocol v1.0 01Aug2025.pdf" version="1.0" mimeType="application/pdf" length="573139" md5sum="ad91998e7c5c05128b5ab8bf78e050e9"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>0ed03880-a2d5-49e4-a6d9-03fa53e15d13</funderId>
      <contactId>219fe7a6-e1c0-45b4-8338-30f536557b58</contactId>
      <contactId>92656118-54cf-4bcf-b068-f88abfd36fc4</contactId>
      <contactId>8d6af225-90e4-4a42-b9c6-f5fe3fd13343</contactId>
      <sponsorId>dce9aedd-281c-4e28-bb73-288c21115807</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/45394494-5e85-478f-8d1c-39937f5b12cd/50104">
	<description>Participant information sheet</description>
	<name>50104 Participant Information Sheet (Service User) v1.0 01Aug2025.pdf</name>
	<id>45394494-5e85-478f-8d1c-39937f5b12cd</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>146239</length>
	<md5sum>3af1c3a85d45ec9bb5612e67209e5c80</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/b55bee6e-57bc-4e53-a6be-a2e75c5c94b5/50104">
	<description>Protocol file</description>
	<name>50104 Protocol v1.0 01Aug2025.pdf</name>
	<id>b55bee6e-57bc-4e53-a6be-a2e75c5c94b5</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>573139</length>
	<md5sum>ad91998e7c5c05128b5ab8bf78e050e9</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="219fe7a6-e1c0-45b4-8338-30f536557b58">
    <title>Dr</title>
    <forename>Stephanie</forename>
    <surname>Howarth</surname>
    <orcid/>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Birmingham
52 Pritchatts Road, Edgbaston</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 121 414 3344</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.l.howarth@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="92656118-54cf-4bcf-b068-f88abfd36fc4">
    <title>None</title>
    <forename>Anna</forename>
    <surname>Amiry</surname>
    <orcid>https://orcid.org/0000-0002-0912-3387</orcid>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Psychology
University of Birmingham
52 Pritchatts Road, Edgbaston</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 121 414 3344</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">axa2572@student.bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="8d6af225-90e4-4a42-b9c6-f5fe3fd13343">
    <title>Dr</title>
    <forename>Carl</forename>
    <surname>Krynicki</surname>
    <orcid>https://orcid.org/0000-0003-0943-5142</orcid>
    <contactTypes>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Psychology
University of Birmingham
52 Pritchatts Road, Edgbaston</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 121 414 3344</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.krynicki@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="dce9aedd-281c-4e28-bb73-288c21115807">
    <organisation>University of Birmingham</organisation>
    <sponsorType/>
    <rorId>https://ror.org/03angcq70</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="0ed03880-a2d5-49e4-a6d9-03fa53e15d13">
    <name>Investigator initiated and funded</name>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-09-09T14:44:31.79701824Z" version="11" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN11648926" publicIdentifierDateAssigned="2026-09-11T12:57:12.429067Z">
    <isrctn dateAssigned="2026-09-11T12:57:12.429067Z">11648926</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A 6-week study to assess the safety, comfort and potential benefits of a toothpaste containing 5% SiPore</title>
      <scientificTitle>A 6-week, double-blind, randomised controlled trial to assess the safety, tolerability and preliminary efficacy of a 5% SiPore-containing toothpaste</scientificTitle>
      <acronym>AMYLO-STOP Tolerability Trial</acronym>
      <studyHypothesis>Primary objective:
To assess the safety of twice-daily use of a 5% SiPore-containing toothpaste over 6 weeks, compared with a control toothpaste with the same base formula but without SiPore, in adults with mild-moderate gingival inflammation. 

Secondary safety and tolerability objectives: 
1. To assess changes in plaque accumulation from baseline to 6 weeks
2. To assess changes in gingival inflammation from baseline to 6 weeks

Exploratory objectives:
1. To collect saliva samples for analyses of the oral microbiome</studyHypothesis>
      <plainEnglishSummary>Background and study aims 
This study will look at the safety of a new toothpaste containing 5% SiPore and whether people are able to use it without unwanted effects. SiPore is a specially designed form of silica. Similar types of silica have previously been tested in people and have generally been found to be safe and well tolerated when taken by mouth.The main purpose of the study is to find out whether using toothpaste containing 5% SiPore causes any side effects, discomfort or irritation in the mouth.

Who can participate? 
Adults aged 18 to 60 years with mild to moderate gum inflammation 

What does the study involve? 
Participants will be randomly placed into one of two groups. One group will use a toothpaste containing 5% SiPore and the other group will use a control toothpaste that looks, tastes and feels the same but does not contain SiPore. Participants will use their allocated toothpaste for 6 weeks.
The study will also look at whether the toothpaste may have benefits for oral health. We will assess changes in the amount of dental plaque, gum inflammation and overall gum health. We will also look at the types of bacteria found in the mouth to see whether the toothpaste affects the balance of the oral bacterial community.

What are the possible benefits and risks of participating? 
The results of this study will help us understand whether toothpaste containing 5% SiPore is suitable for wider use and will provide early information about whether it may have benefits for oral health.

Where is the study run from? 
Birmingham Dental Hospital (UK)

When is the study starting and how long is it expected to run for? 
September 2026 to December 2026

Who is funding the study? 
Orkla Health AS (Norway)

Who is the main contact? 
Dr Praveen Sharma, p.sharma@bham.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="d9a818c9-9e1b-41c0-be90-7995a390b3d2">
	  <variable>The proportion of participants experiencing at least one serious treatment-emergent oral adverse event in the 5% SiPore and control toothpaste groups,</variable>
	  <method>a combination of clinical assessments (Turesky Plaque Index [TPI] for plaque accumulation, Modified Gingival Index [MGI] for gingival inflammation, assessment of oral hard and soft tissue conditions), participant-reported outcomes (including taste, texture, oral comfort and willingness to continue use), investigational product accountability records and biological sample collection. Data will be collected</method>
	  <timepoints>the baseline and 6-week timepoints by trained and calibrated study staff using standardised electronic case report forms (eCRFs). Participant-reported data will be collected using self-reported, questions such as 1) Would you switch from your current toothpaste to this toothpaste? 2) Would you recommend this toothpaste? 3) Do you feel cleaner after brushing with this toothpaste than with other toothpastes? Compliance data will be collected through participant self-report and return of used investigational product, with visual inspection of toothpaste tubes undertaken. Saliva samples will be collected according to a standardised sample collection procedure and used for exploratory oral microbiome analyses to investigate changes in oral microbiome with use of test or control toothpastes.</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="df895045-816e-4d30-93e1-f2259c21cefc">
	  <variable>Differences in any treatment-emergent oral adverse events including oral mucosal sloughing, oral ulceration, taste, texture, oral comfort and willingness to continue use between the test and the control toothpaste,</variable>
	  <method>a combination of clinical assessments (TPI for plaque accumulation, MGI for gingival inflammation, assessment of oral hard and soft tissue conditions), participant-reported outcomes (including taste, texture, oral comfort and willingness to continue use), investigational product accountability records and biological sample collection. Data will be collected</method>
	  <timepoints>the baseline and 6-week timepoints by trained and calibrated study staff using standardised electronic case report forms (eCRFs).</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="d188035e-dc61-4d2b-a2f4-933107c045b7" approvalStatus="approved" statusDate="2026-09-09T00:00:00.000Z">
	  <committeeName>Wales Research Ethics Committee 5</committeeName>
	  <contactDetails>
	    <address>Floor 4, Crown Building</address>
	    <city>Cardiff</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>CF10 3NQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/WA/0215</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11648926</doi>
      <eudraCTNumber/>
      <irasNumber>372427</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber/>
      <secondaryNumbers>
	<secondaryNumber id="54d1c127-5c0a-4911-b8b9-707c532e9ecc" numberType="iras" canonicalSecondaryNumber="IRAS372427">372427</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2026-12-11T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0ca73857-5b07-4b48-8770-0647f5e29b33">
	  <name>Birmingham Dental Hospital</name>
	  <address>St. Chads Queensway</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B4 6NN</zip>
	  <rtsId>RYW21@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>true</healthyVolunteersAllowed>
      <inclusion>1. Aged 18 to 60 years, inclusive, at the time of screening
2. Able and willing to provide written informed consent
3. Willing and able to comply with all scheduled visits and all study procedures
4. In good general and mental health, with no condition that, in the opinion of the investigator or medically qualified designee, would: 
4.1. Affect the participant’s safety or wellbeing
4.2. Affect the study outcomes
4.3. Or impair the participant’s ability to understand and follow study procedures and requirements
5. At screening, meeting all of the following oral health criteria
5.1. At least 20 natural permanent teeth, excluding third molars
5.2. Mild to moderate gingivitis defined as 10% ≤ BS ≤ 30%</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="60.0">60 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Participation in another study involving investigational product(s), including non-medicinal studies, within 30 days before study entry or during participation
2. Any acute or chronic medical or psychiatric condition, serious or unstable condition, including cardiovascular disease, diabetes, liver or kidney disorder, that may increase risk, affect safety, interfere with study outcomes, or make participation inappropriate
3. Pregnant, intending to become pregnant during the study, or breastfeeding
4. Known or suspected intolerance or hypersensitivity to study materials, ingredients or related compounds
5. On a restricted carbohydrate or starch diet
6. Unwilling or unable to comply with protocol lifestyle considerations
7. Current smoker, current vaper, ex-smoker or ex-vaper who stopped within 6 months of screening, or user of smokeless tobacco, including chewing tobacco, gutkha, pan containing tobacco, or nicotine-based e-cigarettes
8. Medical condition or bleeding disorder that could influence gingival bleeding, study outcomes or participant safety
9. Severe oral conditions that could compromise study outcomes or participant/examiner safety
10. Tongue or lip piercing, or any other oral feature that could interfere with toothbrush use
11. Medication exclusions
11.1. Antibiotic medication within 28 days before screening or use during the study
11.2. Oral care product containing antibacterial agents, for example chlorhexidine, or any ingredient considered likely to affect plaque formation or gingival health within 4 weeks of screening
12.	Periodontal exclusions: 
12.1. Signs of periodontitis, defined as any site, not including wisdom teeth, with probing pocket depth ≥3.5 mm
12.2. Periodontal treatment within 12 months of screening
13.	Dental exclusions: 
13.1. Caries, restorations or dental conditions that could compromise outcomes or oral health
13.2. Partial or full dentures
13.3. Fixed orthodontic appliances or orthodontic treatment within 3 months of screening 
13.4. Other orthodontic devices, including bands, fixed retainers or removable retainers, likely to interfere with study procedures, assessments or outcomes
13.5. Dental prophylaxis within 12 weeks of screening
13.6. Teeth bleaching within 12 weeks of screening
13.7. High levels of calculus deposits
13.8. Any other reason that, in the opinion of the study dentist or suitably qualified designee, makes participation inappropriate</exclusion>
      <recruitmentStart>2026-09-14T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2026-09-25T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mild-moderate gingival inflammation</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants will be randomised in a 1:1 ratio to receive either the 5% SiPore-containing toothpaste or the control toothpaste with the same base formulation but without SiPore. Randomisation will occur at the baseline visit, once eligibility has been confirmed and all baseline assessments have been completed. Randomisation will be stratified by sex (male/female) and percentage of bleeding sites (&lt;15% or ≥15%). The randomisation schedule will be generated using online, randomisation software. Allocation will be concealed until the point of assignment, using study product codes or an equivalent secure allocation system.

Participants will be asked to use their allocated toothpaste twice daily for the duration of the study. Data and samples to assess primary and secondary outcomes will be collected at baseline and at the 6-week visit.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>3cb88886-17d9-4cc4-8e2a-54399b9e1966</funderId>
      <contactId>8908fcb4-da7b-4ad9-9d8d-7c04693a66dc</contactId>
      <sponsorId>04d7c80d-8cb3-4d38-8868-cf130b04f4f0</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="8908fcb4-da7b-4ad9-9d8d-7c04693a66dc">
    <title>Dr</title>
    <forename>Praveen</forename>
    <surname>Sharma</surname>
    <orcid>https://orcid.org/0000-0001-6435-4842</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Birmingham Dental Hospital
5 Mill Pool Way</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B5 7SA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 466 5128</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.sharma@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="04d7c80d-8cb3-4d38-8868-cf130b04f4f0">
    <organisation>Orkla (Norway)</organisation>
    <sponsorType/>
    <rorId>https://ror.org/04a839673</rorId>
    <commercialStatus>Commercial</commercialStatus>
  </sponsor>
  <funder id="3cb88886-17d9-4cc4-8e2a-54399b9e1966">
    <name>Orkla Health AS</name>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-10-07T15:22:52.960129051Z" version="17" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN14945909" publicIdentifierDateAssigned="2026-08-03T13:34:01.30716Z">
    <isrctn dateAssigned="2026-08-03T13:34:01.30716Z">14945909</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of a ketogenic diet and NHS healthy eating guidance for bipolar depression: a randomised controlled trial</title>
      <scientificTitle>Evaluating nutritional ketosis versus NHS Eatwell guide for bipolar depression: single blind randomised controlled trial</scientificTitle>
      <acronym>ENERGISE-BD</acronym>
      <studyHypothesis>To determine the efficacy of nutritional ketosis in comparison to the NHS EatWell guide (9) for the treatment of bipolar depression.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Bipolar disorder is a mental health condition which causes repeated episodes of low and high mood. Many people with bipolar disorder also experience long-lasting symptoms of depression, which can significantly affect everyday life. The current understanding of how bipolar disorder develops remains unclear, and treatments for the depressive symptoms are not always effective and often have unwanted side effects. Some evidence suggests that changes in diet might help treat depressive symptoms in bipolar disorder, so we are doing this study to investigate this further.
We think certain diets could reduce feelings of depression, and want to know if this is something doctors should recommend in the future.

Who can participate?
Male and female adults (18+ years old) with a diagnosis of bipolar disorder and are currently experiencing bipolar depression.

What does the study involve?
We want to compare the NHS EatWell Guide to nutritional ketosis. The NHS EatWell Guide recommends eating a variety of foods for a balanced diet. Nutritional ketosis is achieved by following a ‘keto’ diet, which is high in fat and very low in carbohydrates, allowing the body to switch to burning fat for energy.
In this study, one group of people follow the nutritional ketosis plan for 12 weeks and the other group follow the NHS EatWell Guide for 12 weeks.
• There is an equal chance of going into each group. We aim to recruit 206 people in total (103 people in each group).
• Participants will know which group they go into.
• We will study how each group gets on to see which one is the most effective as a treatment for bipolar depression.
• We will take the following measurements:
•	Height, weight and blood pressure
•	Blood glucose/ketones
•	Blood sample to assess different markers of physical health
•	Urine test to check if pregnant (if relevant)
•	A series of questionnaires, which will ask about the participants mental health and physical health 
•	Some of the participants in the study who are based in Edinburgh will undergo a Magnetic Resonance Spectroscopy scan of the brain.

What are the possible benefits and risks of participating?
Potential benefits of taking part in this study include:
•	Learning more about your mental health and mood over the time you spend in the study, and how they relate to changes in your diet.
•	Education and advice on a dietary intervention from a qualified dietitian.
•	The results from this study may help us to improve treatments for people with bipolar depression in the future, and your participation could make a meaningful impact on this important area of research.
•	We will reimburse participants for their time and travel expenses.
The disadvantages are that participants may find the study time-consuming, as it will last 24 weeks and require you to attend 3 to 4  face-to-face appointments depending on whether they are one of the participants who will undergo brain scans (Magnetic Resonance Spectroscopy).
Appointments will include questionnaires which may take some time and ask sensitive questions about the participants personal and mental health history, which some participants may find upsetting.
Dietary changes may cause side effects including stomach upset, nausea, vomiting, changes in bowel habits (particularly constipation), hunger, thirst, tiredness, irritability, weight loss, low blood sugar (hypoglycaemia), high levels of fat in the blood (hyperlipidaemia), high levels of ketones in the blood, leg cramps, or irregular periods in women. As nutritional ketosis involves eating a high proportion of fat, it may increase levels of fat in the blood (cholesterol and triglycerides).  
Blood tests may be uncomfortable or upsetting, and they may cause small bruises. 
There is a small chance that blood tests or brain scans might find unexpected abnormalities. 
A minority of people find Magnetic Resonance Spectroscopy brain scans anxiety-provoking and may experience a fear of small spaces (claustrophobia) during the scans. 

Where is the study run from?
The University of Edinburgh and NHS Lothian (UK)

When is the study starting and how long is it expected to run for?
October 2026 to July 2030

Who is funding the study?
Wellcome Trust (UK)

Who is the main contact?
Lorna Dewar
energise-bd.trial@ed.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="ac2cb6bb-0615-448e-a967-2a4b59f5ede9">
	  <variable>Proportion of participants in each arm who experience a clinically meaningful response, defined as a drop in PHQ-9 score of 6 or more</variable>
	  <method>Patient Health Questionnaire (PHQ-9)</method>
	  <timepoints>baseline and 12 week post randomisation</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome>1.	Severity of depression symptoms measured using the Patient Health Questionnaire-9 (PHQ-9) at baseline, 12 weeks and 24 weeks post randomisation
2.	Anxiety symptoms measured using the Generalised Anxiety Disorder Questionnaire (GAD-7) at baseline, 12 weeks and 24 weeks post randomisation
3.	Mania symptoms measured using the Altman Self-Rating Mania Scale (ASRM) at baseline, 12 weeks and 24 weeks post randomisation
4.	Health-related quality of life measured using the EuroQol EQ-5D-5L at baseline, 12 weeks and 24 weeks post randomisation
5.	Functional impairment measured using the Functioning Assessment Short Test (FAST) at baseline, 12 weeks and 24 weeks post randomisation
6.	Concurrent medication use (psychiatric and other medications) measured using study-recorded medication data at baseline, 12 weeks and 24 weeks post randomisation
7.	Continuation of allocated diet intervention measured using study-recorded intervention adherence data at baseline, 12 weeks and 24 weeks post randomisation
8.	Feasibility of collecting health economic resource use consequences and associated costs of a nutritional ketosis intervention compared to the NHS EatWell Guide for bipolar depression measured using a bespoke health economic resource use questionnaire at 12 weeks and 24 weeks post randomisation
9.	Body mass index (BMI) measured using BMI calculated from measured height and weight at baseline and 12 weeks post randomisation
10.	Weight change from baseline (percentage) measured using percentage change in body weight calculated from measured weight at baseline and 12 weeks post randomisation
11.	Blood pressure (BP) measured using blood pressure measurement at baseline and 12 weeks post randomisation
12.	Glycated haemoglobin (HbA1c) measured using an HbA1c blood test at baseline and 12 weeks post randomisation
13.	Insulin resistance (C-peptide and glucose) measured using blood tests for C-peptide and glucose at baseline and 12 weeks post randomisation
14.	Lipid profile (total cholesterol, triglycerides, cholesterol/HDL ratio and non-HDL cholesterol) measured using a lipid profile blood test at baseline and 12 weeks post randomisation
15.	Renal function (urea and electrolytes [U&amp;Es]) measured using a urea and electrolytes blood test at baseline and 12 weeks post randomisation
16.	Liver function measured using liver function tests (LFTs) at baseline and 12 weeks post randomisation
17.	Plasma lactate measured using a plasma lactate blood test at baseline and 12 weeks post randomisation
18.	Blood ketone levels measured using a KetoMojo device daily from baseline to 12 weeks post randomisation
19.	Blood glucose levels measured using a KetoMojo device daily from baseline to 12 weeks post randomisation
20.	Magnetic Resonance Spectroscopy (MRS) markers of brain energetics: Estimated molal tissue concentration of glutamate plus glutamine (Glx), and lactate (Lac), phosphocreatine/ATP signal ratio and intracellular pH measured using Magnetic Resonance Spectroscopy (MRS) assessments of brain metabolites at baseline, 6 weeks and 12 weeks post randomisation</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="edcdaae4-d142-4902-8dc1-8a15a41f3a3f" approvalStatus="approved" statusDate="2026-06-08T00:00:00.000Z">
	  <committeeName>East Midlands – Leicester South Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>Health Research Authority
3 Piccadilly Place
London Road
Manchester</address>
	    <city>Manchester</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>M1 3BN</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/EM/0140</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14945909</doi>
      <eudraCTNumber/>
      <irasNumber>370428</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 76325</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="e82ebb72-f7bb-4f25-800c-01831cb64f5a" numberType="iras" canonicalSecondaryNumber="IRAS370428">370428</secondaryNumber>
	<secondaryNumber id="c4c2b535-3dc1-452a-adbc-b0dd0e32e723" numberType="cpms" canonicalSecondaryNumber="CPMS76325">76325</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2030-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Scotland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="56f2d26c-8e53-4475-b470-1160ff5ed386">
	  <name>Royal Infirmary of Edinburgh at Little France</name>
	  <address>51 Little France Crescent
Old Dalkeith Road
Edinburgh</address>
	  <city>Lothian</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>EH16 4SA</zip>
	  <rtsId>S314H@2.16.840.1.113883.2.1.3.8.2.16.2</rtsId>
	</trialCentre>
	<trialCentre id="8ba40ce7-c476-43cb-b1fc-39401e5edef8">
	  <name>The Barberry</name>
	  <address>25 Vincent Drive</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B15 2FG</zip>
	  <rtsId>RXT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Adults (aged 18 and over) with a primary* diagnosis of bipolar disorder (BD-I or BD-II), confirmed by the Structured Clinical Interview for DSM5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), (SCID5)
2. Bipolar depression symptoms of at least moderate clinical severity on the PHQ-9 (defined as a score of 10 or above)
*Other comorbid psychiatric diagnoses are permitted (apart from eating disorders and substance misuse/dependence)</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>206</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>Current key exclusion criteria as of 11/08/2026: 

1.	Currently in need of acute inpatient, crisis resolution, or home treatment services
2.	Does not have capacity to consent
3.	Previous use of nutritional ketosis within 2 months
4.	Current use of weight loss medications (such as semaglutide or tirzepatide)
5.	Inability to complete mandatory study assessments
6.	No access to a smartphone and/or unwilling to add the KetoMojo app to their smartphone
7.	Specific contraindications for the nutritional ketosis intervention:
7.1. Pregnancy, breastfeeding, or planning to become pregnant within 3 months 
7.2. Liver failure 
7.3. Pancreatitis (acute and past history) 
7.4. Chronic kidney disease 
7.5. Type I diabetes 
7.6. Use of SGLT-2 inhibitors 
7.7. Recent stroke or myocardial infarction 
7.8. Heart failure 
7.9. Cardiac arrhythmias 
7.10. Respiratory failure 
7.11. Active infections 
7.12. Cancer 
7.13. Hyperuricaemia 
7.14. Severe hyperlipidaemia (familial hypercholesterolaemia, severe hypertriglyceridemia, or a documented medical history of high total cholesterol &gt;7.5 mmol/L)
7.15. Participant-reported inborn error of metabolism affecting fatty acid transport/oxidation, including organic acidurias and mitochondrial fatty acid beta-oxidation disorders
8.	Past history of an eating disorder (bulimia or anorexia)
9.	Currently only eating a vegan or exclusively plant-based diet
10.	Other major primary psychiatric disorder that is not bipolar disorder, or major neurological disorders
11.	Harmful current use of or dependence on psychoactive substances (including alcohol)
12.	Currently enrolled in an interventional research study

_____

Previous key exclusion criteria:

1.	Currently in need of acute inpatient, crisis resolution, or home treatment services
2.	Does not have capacity to consent
3.	Previous use of nutritional ketosis within 2 months
4.	Current use of weight loss medications (such as semaglutide or tirzepatide)
5.	Inability to complete mandatory study assessments
6.	No access to a smartphone and/or unwilling to add the KetoMojo app to their smartphone
7.	Specific contraindications for the nutritional ketosis intervention:
7.1. Pregnancy, breastfeeding, or planning to become pregnant within 3 months 
7.2. Liver failure 
7.3. Pancreatitis (acute and past history) 
7.4. Chronic kidney disease 
7.5. Type I diabetes 
7.6. Use of SGLT-2 inhibitors 
7.7. Recent stroke or myocardial infarction 
7.8. Heart failure 
7.9. Cardiac arrhythmias 
7.10. Respiratory failure 
7.11. Active infections 
7.12. Cancer 
7.13. Hyperuricaemia 
7.14. Severe hyperlipidaemia (familial hypercholesterolaemia, severe hypertriglyceridaemia, or total cholesterol &gt;7.5 mmol/L) 
7.15. Participant-reported inborn error of metabolism affecting fatty acid transport/oxidation, including organic acidurias and mitochondrial fatty acid beta-oxidation disorders
8.	Past history of an eating disorder (bulimia or anorexia)
9.	Currently only eating a vegan or exclusively plant-based diet
10.	Other major primary psychiatric disorder that is not bipolar disorder, or major neurological disorders
11.	Harmful current use of or dependence on psychoactive substances (including alcohol)
12.	Currently enrolled in an interventional research study</exclusion>
      <recruitmentStart>2026-10-14T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2029-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bipolar depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>ENERGISE-BD is a single blind randomised controlled trial of nutritional ketosis versus the NHS EatWell guide for the treatment of bipolar depression.  

Participants will be randomised in a 1:1 ratio to either the nutritional ketosis intervention or the NHS EatWell Guide control group using a secure online randomisation system designed and managed by the Edinburgh Clinical Trials Unit (ECTU).

Nutritional ketosis intervention: Participants will follow a modified ketogenic diet for 12 weeks, providing approximately 60–75% of estimated energy requirements from fat, 5–7% from carbohydrates, with the remaining energy provided by protein. For the first two weeks pre-prepared meals will provide the required daily calorie and macronutrient composition and will be tailored to individual dietary requirements. 

NHS EatWell Guide control:  Participants will follow a diet based on the NHS EatWell Guide for 12 weeks, which promotes a healthy, balanced diet comprising fruit and vegetables, starchy carbohydrates, lean sources of protein, dairy or suitable alternatives, and healthy fats, with smaller amounts of foods high in fat, salt and sugar.

The allocated dietary intervention will last for 12 weeks. Participants will attend in-person study visits at baseline, 6 weeks and 12 weeks. During the 12-week intervention, participants in both groups will have weekly remote contact with a study dietitian to provide dietary support and monitor adherence to their allocated diet. At the end of the 12-week intervention, participants will be supported during a 2-week phase-out from their allocated diet. A final follow-up appointment will be conducted remotely at 24 weeks.

Brain imaging substudy:  At the Edinburgh site, approximately 72 eligible participants without contraindications to magnetic resonance (MR) scanning (approximately 36 from each treatment arm) will undergo 1-hour 3T MR scans at baseline, 6 weeks and 12 weeks. Imaging will include anatomical brain imaging for the detection of incidental pathology and positioning of magnetic resonance spectroscopy (MRS) volumes of interest.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study will be stored in a publicly available repository: Edinburgh DataShare.

Following publication of the primary study results, anticipated approximately 9–12 months after the end of the project, de-identified participant-level data, together with relevant supporting metadata and documentation, will be made available via Edinburgh DataShare for secondary research purposes. Data will remain available in accordance with the repository’s preservation and access policies.

Imaging data, including images and spectra, are potentially re-identifiable and will therefore be stored securely on University of Edinburgh servers rather than in a publicly accessible repository. Requests to access these data, or for other data-sharing activities not specified in the protocol, will be reviewed in accordance with ECTU data-sharing procedures.

Access will be subject to participant consent and applicable ethical, legal and information governance requirements. Requests will be assessed according to factors including the proposed purpose and scientific merit, suitability of the requester, data requested and risk of re-identification. Where approved, the minimum necessary data will be shared in the least identifiable form using an appropriately secure mechanism and subject to any required agreements.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Stored in publicly available repository</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>f184ff95-1834-4693-81ef-5d91924e8b47</funderId>
      <contactId>e4d03f9a-cab6-4e96-83c5-3cdbc6ada87e</contactId>
      <contactId>2f53fb96-79d3-4a97-b840-7c03b0c5d75a</contactId>
      <contactId>1db7987c-e1cc-4be2-bec7-fca508605d13</contactId>
      <contactId>4f8d7c5b-26d2-48c5-89fa-9dcc6be86c7e</contactId>
      <sponsorId>cfa467ba-8d80-4c85-b208-0f329498a11f</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="e4d03f9a-cab6-4e96-83c5-3cdbc6ada87e">
    <title>Prof</title>
    <forename>Daniel</forename>
    <surname>Smith</surname>
    <orcid>https://orcid.org/0000-0002-2267-1951</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>The Royal Infirmary of Edinburgh 
51 Little France Crescent
Old Dalkeith Road
Edinburgh</address>
      <city>Edinburgh</city>
      <state/>
      <country>United Kingdom</country>
      <zip>EH16 4SA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 7734463270</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">d.smith@ed.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="2f53fb96-79d3-4a97-b840-7c03b0c5d75a">
    <title>Prof</title>
    <forename>Steven</forename>
    <surname>Marwaha</surname>
    <orcid>https://orcid.org/0000-0002-0303-9942</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Birmingham and Solihull Mental NHS Foundation Trust</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B13 8QY</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.marwaha@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="1db7987c-e1cc-4be2-bec7-fca508605d13">
    <title>Miss</title>
    <forename>Lorna</forename>
    <surname>Dewar</surname>
    <orcid>https://orcid.org/0009-0009-7260-4165</orcid>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>ECTU, Usher Building  The University of Edinburgh Edinburgh BioQuarter 5-7 Little France Road</address>
      <city>Edinburgh</city>
      <state/>
      <country>United Kingdom</country>
      <zip>EH16 4UX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">energise-bd.trial@ed.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="4f8d7c5b-26d2-48c5-89fa-9dcc6be86c7e">
    <title>Prof</title>
    <forename>Rebecca</forename>
    <surname>Reynolds</surname>
    <orcid>https://orcid.org/0000-0001-6226-8270</orcid>
    <contactTypes>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>The Royal Infirmary of Edinburgh 
51 Little France Crescent
Old Dalkeith Road
Edinburgh</address>
      <city>Edinburgh</city>
      <state/>
      <country>United Kingdom</country>
      <zip>EH16 4SA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">r.reynolds@ed.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="cfa467ba-8d80-4c85-b208-0f329498a11f">
    <organisation>University of Edinburgh and NHS Lothian</organisation>
    <sponsorType/>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="f184ff95-1834-4693-81ef-5d91924e8b47">
    <name>Wellcome</name>
    <fundRef>http://dx.doi.org/10.13039/100004440</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-07-27T15:49:07.367663806Z" version="15" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN30583116" publicIdentifierDateAssigned="2026-07-27T15:49:07.493213Z">
    <isrctn dateAssigned="2026-07-27T15:49:07.493213Z">30583116</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>How can we improve care for patients recovering from acute pancreatitis following discharge from hospital?</title>
      <scientificTitle>oPtimising post-dischArge care pathways after acute paNcreatitis: evaluatiOn of health seRvice utilisAtion, outcoMes</scientificTitle>
      <acronym>PANORAMA</acronym>
      <studyHypothesis>1.	Develop conceptual framework for a ‘gold-standard’ post-hospital discharge pathway (WP1)
2.	Explore patient experience of post-hospital discharge care (WP2)
3.	Explore clinician approaches to post-discharge care (WP3)
4.	Describe real-world pathways experienced by patients after hospital discharge (WP4)
5.	Identify groups at highest risk of use of health care services (WP2&amp;4)
6.	Co-produce interventions for post-discharge care pathways (WP5)</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Acute pancreatitis is a common condition that causes inflammation of the pancreas and leads to thousands of hospital admissions in the UK each year. Although most people recover enough to leave hospital, many continue to experience health problems after discharge. These can include difficulties with digestion, problems controlling blood sugar, anxiety, depression, and ongoing pain. Some people also return to hospital after they have been discharged.

At present, there is no standard approach to follow-up care after acute pancreatitis in the UK. The PANORAMA study aims to understand what support people need after leaving hospital, how current care pathways are working, and how care could be improved. The researchers also want to identify which patients are most likely to need additional support or further healthcare after discharge. Findings from the study will be used to develop recommendations for future care pathways.

Who can participate?
Different parts of the study involve different groups of people:
1. People aged 16 years or over who have experienced acute pancreatitis and received care through the NHS
2. Family members or carers of people who have experienced acute pancreatitis
3. Healthcare professionals involved in caring for patients with acute pancreatitis, including hospital doctors, specialist nurses, allied health professionals and GPs
4. Patients currently in hospital with acute pancreatitis who are due to be discharged and are able to give informed consent

The study is recruiting participants from across the United Kingdom.

What does the study involve?
The study is made up of five linked work packages (WP).

In WP1, patients, carers and healthcare professionals will be invited to complete a survey about their experiences and views of care after discharge from hospital.

In WP2, some patients and carers will be invited to take part in a virtual interview lasting up to 1 hour. Participants will discuss their experiences after leaving hospital and describe what they think could improve care.

In WP3, healthcare professionals will take part in similar interviews to explore their experiences of supporting patients after acute pancreatitis and their views on how care could be improved.

In WP4, patients who are about to be discharged from hospital after acute pancreatitis will be asked to complete questionnaires about their quality of life, mental health, digestive health and healthcare use. These questionnaires will be completed at discharge and then again after 7 days, 28 days, 3 months and 6 months. Each questionnaire session may take up to 30 minutes.

In WP5, selected patients, carers and healthcare professionals will be invited to attend a workshop to discuss the study findings and help develop recommendations for improving care after acute pancreatitis.

What are the possible benefits and risks of participating?
Participants may not receive any direct medical benefit from taking part. However, their experiences and opinions could help researchers understand how care after acute pancreatitis can be improved. The findings may help shape future services and support for patients recovering from this condition.

The risks of participation are expected to be low. Some people may find it upsetting to discuss their experiences of illness during interviews. If a participant becomes distressed, the interview can be paused or stopped, and information about support services can be provided. Participants in the questionnaire study who report signs of severe mental distress or risk of self-harm will be advised to seek help from NHS 111 or their GP.

Where is the study run from?
The study is sponsored and led by the University of Birmingham and is being conducted in collaboration with NHS hospitals across England and Scotland. Participant data will be managed through secure systems hosted by the University of Birmingham.

When is the study starting and how long is it expected to run for?
July 2026 to September 2027.

Who is funding the study?
The study is funded by the National Institute for Health and Care Research (NIHR).

Who is the main contact?
Dr Michala Pettitt
panorama-study@contacts.bham.ac.uk&gt;</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="c68d1552-ac86-45e0-8889-4c7f49eccbd9">
	  <variable>WP1: Identification of the opportunities that exist to improve care after discharge from hospital following acute pancreatitis</variable>
	  <method>survey of stakeholders to identify the key features and characteristics that define a ‘good’ follow-up pathway for patients with AP.  Qualitative content analysis using a thematic approach</method>
	  <timepoints>until saturation is reached (40 patients/ carers, 40 clinicians)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="31ae84f8-d8ea-44ea-83c0-92070d005ca7">
	  <variable>WP2: Commentary describing the experiences of participants (patients and their carers) following discharge from hospital with acute pancreatitis</variable>
	  <method>purposive selection of candidates completing an EoI to maximise sampling across collected descriptors (sex, ethnicity, aetiology, region), followed by semi-structure interviews (informed by analysis of WP1) and qualitative thematic analysis</method>
	  <timepoints>Following analysis of WP1 to run concurrently with WP3 and WP4</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9f2090b3-51d2-4521-a715-ee15b07c36dd">
	  <variable>WP3: Commentary describing the experiences of NHS clinicians with responsibilities for the care of patients with AP</variable>
	  <method>purposive selection of candidates completing an EoI to maximise sampling across collected descriptors (sex, ethnicity, aetiology, region), followed by semi-structure interviews (informed by analysis of WP1) and qualitative thematic analysis</method>
	  <timepoints>following analysis of WP1 to run concurrently with WP2 and WP4</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="48caaa50-70d5-4f3b-803e-0477c4d80831">
	  <variable>WP4: Patient demographics, Patient co-morbidities, Prior diagnosis of mental health issues, Disease aetiology and inpatient treatment, Clinician planned follow-up on discharge</variable>
	  <method>patient records</method>
	  <timepoints>baseline</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="6edd65e5-4c6b-47f2-a7d1-a7182fb44c4c">
	  <variable>WP4: Alcohol usage</variable>
	  <method>AUDIT-C PROM</method>
	  <timepoints>baseline</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="10e9f88a-3aa5-4cca-8148-f9b89cafe7e8">
	  <variable>WP4: Patient quality of life</variable>
	  <method>EQ-5D-5L PROM</method>
	  <timepoints>discharge, 7 days, 30 days, 3 months, 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="e42cc58d-6c83-44c2-886d-7f495e6e63d7">
	  <variable>WP4: Patient anxiety</variable>
	  <method>GAD-7 PROM</method>
	  <timepoints>discharge, 7 days, 30 days, 3 months, 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="51e4e232-fb01-4716-a9a1-d29cc8c63d16">
	  <variable>WP4: Patient depression</variable>
	  <method>PHQ-9 PROM</method>
	  <timepoints>discharge, 7 days, 30 days, 3 months, 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="37a38b2d-8a13-401d-bfe3-40fa916d42c2">
	  <variable>WP4: Patient endocrine insufficiency score</variable>
	  <method>PEI-Q PROM</method>
	  <timepoints>discharge, 7 days, 30 days, 3 months, 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="91af81d0-1800-4a94-8957-ad2a1b18b4c4">
	  <variable>WP4: Healthcare utilisation following discharge</variable>
	  <method>Healthcare Utilisation PROM</method>
	  <timepoints>30 days, 3 months, 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="f3b26c3b-bf63-4e83-a5b8-2e1121adc9ed">
	  <variable>WP5: Identification of opportunities to implement the findings from WP1-4</variable>
	  <method>data from WP1-4 will be triangulated to identify commonalities and differences.  These analyses will form the basis of discussions in a one-day stakeholder workshop. Rolfe’s Co-reflective model ‘What?, So What?, Now What?’ will be used as a framework to identify opportunities to amend post-discharge pathways for patients following hospitalisation with acute pancreatitis</method>
	  <timepoints>the end of analysis of preceding WP1-4</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="523914b5-d289-42bd-a3e3-6cfc66aaa7f4" approvalStatus="approved" statusDate="2026-05-13T00:00:00.000Z">
	  <committeeName>South Central - Oxford B Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/SC/0148</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN30583116</doi>
      <eudraCTNumber/>
      <irasNumber>349680</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 64883, NIHR: 165210</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="fada9237-880f-40bc-b569-c081e9d1150f" numberType="iras" canonicalSecondaryNumber="IRAS349680">349680</secondaryNumber>
	<secondaryNumber id="7ef4157c-0d60-44d9-804a-5948dd4f6dec" numberType="cpms" canonicalSecondaryNumber="CPMS64883">64883</secondaryNumber>
	<secondaryNumber id="76abc018-accc-4fbf-a98b-04b0d76817f1" numberType="nihr" canonicalSecondaryNumber="NIHR165210">165210</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2027-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Scotland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="59a26d97-7e2c-4fcd-a834-c528816493c3">
	  <name>University Hospitals Birmingham NHS Foundation Trust</name>
	  <address>Queen Elizabeth Hospital
Mindelsohn Way
Edgbaston</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B15 2GW</zip>
	  <rtsId>RRK@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="aa1148cb-fecd-4bcc-9b48-2827b359afaf">
	  <name>Somerset NHS Foundation Trust</name>
	  <address>Trust Management
Lydeard House
Musgrove Park Hospital</address>
	  <city>Taunton</city>
	  <state/>
	  <country>England</country>
	  <zip>TA1 5DA</zip>
	  <rtsId>RH5@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="e5215641-a57f-4a0c-b180-961523284999">
	  <name>Leeds Teaching Hospitals NHS Trust</name>
	  <address>St. James's University Hospital
Beckett Street</address>
	  <city>Leeds</city>
	  <state/>
	  <country>England</country>
	  <zip>LS9 7TF</zip>
	  <rtsId>RR8@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="7f360bf6-23a2-4bc1-a793-cc28383a8bbf">
	  <name>Manchester University NHS Foundation Trust</name>
	  <address>Cobbett House
Oxford Road</address>
	  <city>Manchester</city>
	  <state/>
	  <country>England</country>
	  <zip>M13 9WL</zip>
	  <rtsId>R0A@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="56500cb9-9ebe-40ad-ba0c-f15265e9bfbc">
	  <name>York and Scarborough Teaching Hospitals NHS Foundation Trust</name>
	  <address>York Hospital
Wigginton Road</address>
	  <city>York</city>
	  <state/>
	  <country>England</country>
	  <zip>YO31 8HE</zip>
	  <rtsId>RCB@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="d3291b15-975c-44a0-87f2-2bdde0477925">
	  <name>Liverpool University Hospitals NHS Foundation Trust</name>
	  <address>Royal Liverpool University Hospital
Prescot Street</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L7 8XP</zip>
	  <rtsId>REM@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1cd6c86e-1b57-4a6c-9a5e-9858fa748114">
	  <name>Oxford University Hospitals NHS Foundation Trust</name>
	  <address>John Radcliffe Hospital
Headley Way
Headington</address>
	  <city>Oxford</city>
	  <state/>
	  <country>England</country>
	  <zip>OX3 9DU</zip>
	  <rtsId>RTH@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="20517c73-26f2-4690-807a-50dcbba14c5f">
	  <name>NHS Lothian</name>
	  <address>Waverley Gate
2-4 Waterloo Place</address>
	  <city>Edinburgh</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>EH1 3EG</zip>
	  <rtsId>SS999@2.16.840.1.113883.2.1.3.8.2.16.1</rtsId>
	</trialCentre>
	<trialCentre id="13ea8b37-9a4c-4ea0-8414-1bdb20719837">
	  <name>South Warwickshire University NHS Foundation Trust</name>
	  <address>Warwick Hospital
Lakin Road</address>
	  <city>Warwick</city>
	  <state/>
	  <country>England</country>
	  <zip>CV34 5BW</zip>
	  <rtsId>RJC@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="d57f2db2-4420-4230-bb22-54b6ed93c21e">
	  <name>University Hospitals Bristol and Weston NHS Foundation Trust</name>
	  <address>Trust Headquarters
Marlborough Street</address>
	  <city>Bristol</city>
	  <state/>
	  <country>England</country>
	  <zip>BS1 3NU</zip>
	  <rtsId>RA7@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="d070fa0d-82fd-4e5c-b871-b9bee8657645">
	  <name>Nottingham University Hospitals NHS Trust</name>
	  <address>Trust Headquarters
Queens Medical Centre
Derby Road</address>
	  <city>Nottingham</city>
	  <state/>
	  <country>England</country>
	  <zip>NG7 2UH</zip>
	  <rtsId>RX1@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="b303fec1-4ba2-4209-9b0a-dc2301512e15">
	  <name>Maidstone and Tunbridge Wells NHS Trust</name>
	  <address>The Maidstone Hospital
Hermitage Lane</address>
	  <city>Maidstone</city>
	  <state/>
	  <country>England</country>
	  <zip>ME16 9QQ</zip>
	  <rtsId>RWF@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="b896c2cc-acf0-4836-aa36-922afa015ea8">
	  <name>Gloucestershire Hospitals NHS Foundation Trust</name>
	  <address>Cheltenham General Hospital
Sandford Road</address>
	  <city>Cheltenham</city>
	  <state/>
	  <country>England</country>
	  <zip>GL53 7AN</zip>
	  <rtsId>RTE@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="64adbfec-2ee2-4efc-b2c7-03c85c6bb825">
	  <name>Torbay and South Devon NHS Foundation Trust</name>
	  <address>Torbay Hospital
Newton Road</address>
	  <city>Torquay</city>
	  <state/>
	  <country>England</country>
	  <zip>TQ2 7AA</zip>
	  <rtsId>RA9@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="a0d1b71b-104e-45cc-ad1a-e417103af543">
	  <name>Greater Glasgow and Clyde</name>
	  <address>Gartnavel Royal Hospital
1055 Great Western Road</address>
	  <city>Glasgow</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>G12 0XH</zip>
	  <rtsId>SG9@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="fbc30b0b-7cca-468e-a80a-eaf112152fbe">
	  <name>North Bristol NHS Trust</name>
	  <address>Southmead Hospital
Southmead Road
Westbury-on-trym</address>
	  <city>Bristol</city>
	  <state/>
	  <country>England</country>
	  <zip>BS10 5NB</zip>
	  <rtsId>RVJ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="02162c66-dfee-4409-ab9c-d549f482773e">
	  <name>University Hospitals of North Midlands NHS Trust</name>
	  <address>Newcastle Road</address>
	  <city>Stoke-on-trent</city>
	  <state/>
	  <country>England</country>
	  <zip>ST4 6QG</zip>
	  <rtsId>RJE@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="5ade0e76-330b-4474-9788-4b9e82aff36a">
	  <name>University Hospitals of Derby and Burton NHS Foundation Trust</name>
	  <address>Royal Derby Hospital
Uttoxeter Road</address>
	  <city>Derby</city>
	  <state/>
	  <country>England</country>
	  <zip>DE22 3NE</zip>
	  <rtsId>RTG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="797aa664-630c-4094-98ef-03ed884d8c8a">
	  <name>Forth Valley</name>
	  <address>Carseview House
Castle Business Park</address>
	  <city>Stirling</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>FK9 4TS</zip>
	  <rtsId>SV9@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="dff121eb-4d4a-49c4-bca4-91d0851d5486">
	  <name>The Shrewsbury and Telford Hospital NHS Trust</name>
	  <address>Mytton Oak Road</address>
	  <city>Shrewsbury</city>
	  <state/>
	  <country>England</country>
	  <zip>SY3 8XQ</zip>
	  <rtsId>RXW@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1524a894-4012-4643-aaad-0644a917a8a2">
	  <name>NHS Grampian</name>
	  <address>Summerfield House
2 Eday Road</address>
	  <city>Aberdeen</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>AB15 6RE</zip>
	  <rtsId>SN999@2.16.840.1.113883.2.1.3.8.2.16.1</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>WP1: Any lived experience of adult acute pancreatitis care in NHS as patient or carer, clinician providing NHS care to patients with acute pancreatitis in secondary or primary care.
WP2: Adults (or their carers) with experience of acute pancreatitis care in the NHS within the preceeding six months. Ideally have a conversational standard of English, but translation can be arranged.
WP3: Clinicians (surgeons, gastroenterologists, specialist nurses, allied health professionals, GPs) providing NHS care to patients with acute pancreatitis.
WP4: People currently admitted to hospital for acute pancreatitis who are due to be discharged. Must be able to consent to participate. 
WP5: Any lived experience of adult acute pancreatitis care in NHS as patient or carer, clinician providing NHS care to patients with acute pancreatitis in secondary or primary care.

Minimum age of participants in any work stream is 16 years old, and participants may be up to 100 years old.</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="16.0">16 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>1017</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>WP1: Must be able to complete survey in English
WP2: Must have experienced care as an adult
WP3: Non UK clinical practice
WP4: Unwilling to consent; no capacity to consent</exclusion>
      <recruitmentStart>2026-06-17T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute pancreatitis</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>There are 5 Work Packages (WP). These are complementary and intended to inform aspects of the final WP5 (see study summary graphic).

WP1: Survey
In order to ensure that themes addressed in the interviews cover all relevant aspects of post discharge care, we will undertake a short initial survey. This will recruit 20-40 from each group of patients/carers, secondary care clinicians (surgeons/gastroenterologists), nursing and allied health professionals, and general practitioners. The survey captures key demographic data, and asks participants to consider what opportunities exist to improve care after discharge, up to 6 months after acute pancreatitis.

WP2: Patient interviews
A topic guide has been prepared and will be refined with information from WP1. We will invite people with lived experience of acute pancreatitis to take part in a virtual interview of up to an hour.

People can register an interest in participation following links from posts on social media and through interest groups, charities, and the NIHR Be Part of Research registry. They will be asked to complete a short expression of interest form. The research team will review expressions of interest and aim to recruit people with a range of experiences by looking at age, gender, ethnicity, geographical region, and whether pancreatitis was related to gallstones.

When an appropriate participant is found, they will be contacted and the study further discussed with them. Should they wish to proceed, a digital consent form will be completed and a meeting arranged. The meeting will be conducted by a non clinical, experience qualitative researcher, and will be conducted by virtual meeting.

The interview will explore experience of post-discharge care after pancreatitis, and what the participant feels might improve this. Should the participant become distressed, the interview will be paused, and terminated if necessary. Signposting to resources such as charities will be undertaken.

Participation is complete at the end of the interview. The recording will be transcribed, and then dual coded by two researchers. A theoretical framework of post discharge needs will be developed using a thematic analysis approach. This will provide the patient perspective on post-discharge care.

WP3: Clinician interviews
A topic guide has been prepared and will be refined with information from WP1. We will invite clinicians who care for people with acute pancreatitis to take part.

People can register an interest in participation following links from posts on social media and emails through specialist clinical associations. They will be asked to complete a short expression of interest form. The research team will review expressions of interest and aim to recruit people with a range of experiences by looking at clinical role, and geographical region.

When an appropriate participant is found, they will be contacted and the study further discussed with them. Should they wish to proceed, a digital consent form will be completed and a meeting arranged. The meeting will be conducted by a non clinical, experience qualitative researcher, and will be conducted by virtual meeting.

The interview will explore experience of post-discharge care after pancreatitis, and what opportunities there are to improve this. This will explore ideas around clinical reasoning and assessment of disease and patient recovery.

Participation is complete at the end of the interview. The recording will be transcribed, and then dual coded by two researchers. A theoretical framework of post pancreatitis health risks and pathway opportunities will be developed. This will provide insight into clinical reasoning and priorities.

WP4: Cohort study
This will recruit people who are due to be discharged from hospital following an episode of acute pancreatitis drawing from several hospitals around the UK. Participants can be approached during their recovery and recruited up to the day of hospital discharge. This is supported by posters in the clinical area, a participant information sheet, and a short video.

If a participant consents, they will complete a set of questionnaires on the day of discharge. These relate to quality of life, mental health, and impact of disease on digestion. These are repeated at day 7, 28, 3 months, and 6 months. There is an additional questionnaire about alcohol use at baseline. We will ask about health service use at 28 days, 3 months, and 6 months post discharge.

Participants will receive reminders to complete by email, sms, or post. All post discharge contact is with the central research team. The questionnaires may take up to 30 minutes to complete.

If a participant reponds to mental health questionnaires indicating high risk of self harm, they will be contacted and advised to seek help via 111 or their GP.

This WP will provide data on health utilisation in the 6 months following discharge. It will provide novel data on the development of anxiety or depression, general quality of life, and patient reported symptoms of pancreatic exocrine insufficiency. We will use these data to construct models to allow us to stratify people who are most likely to use health care services following acute pancreatitis.

WP5: Implementation workshop
People who have shown interest in participation in previous WP will be invited to express interest in participating in a workshop to discuss the findings of the study. We will use purposive sampling to identify those to invite to the workshop. A PIS will be provided to those selected to participate, and consent secured.

This will continue until we have a minimum of 20 participants, 10 of whom are patients or carers, and the remainder a mix of health care professionals with roles in care of acute pancreatitis.

We will present the findings of the study to the whole group. We will then break off into smaller groups to discuss key themes. It is not yet clear what these are, but they may include dietary intervention, mental health support, stratified follow-up, pain management.

Smaller groups of 4-5 participants includind patients and clinicians will discuss a single theme. A facilitator will lead this, using a 'so what, now what' framework. This will encourage reflection, contextualising findings, and encouraging participants to share ideas on how to address these challenges.

We will take fields notes on the discussions and compile a list of 'recommendations to change practice' and 'recommendations for further research'. These ideas and reflections will be presented back to the wider group for comment.

We will share this list with policymakers, clinicians, patients, and researchers to influence future care.

Data will be held on secure servers. Expression of interest and cohort data including PROMS will be captured on REDCap hosted at the University of Birmingham. This is encrypted and password protected, using two factor authentication.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Data sharing statement to be made available at a later date</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="80ad58a7-8e9e-4a76-acfc-b2718e7a0743" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="b48a81a5-d3ce-4331-aaaa-6646e60da2c1" originalFilename="49694 PANORAMA WP2 - PIS (Carer) v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP2 - PIS (Carer) v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="248523" md5sum="0c2c4fce06c569ab0039972ad46c69fe"/>
	<description>WP2 (Carer)</description>
	<productionNotes/>
      </output>
      <output id="38ac5608-f8d3-4fab-9b4e-72c3d7e68440" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="a63d6196-1b78-491d-b4ef-7ad6d6509732" originalFilename="49694 PANORAMA WP2 - PIS (Patient) v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP2 - PIS (Patient) v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="247988" md5sum="86bc26aef761125d83fa7228ae598af0"/>
	<description>WP2 (Patient)</description>
	<productionNotes/>
      </output>
      <output id="76640f92-bca4-4e59-96bd-49eab92a985f" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="02eea570-22d3-4672-860a-8cb32432bd6b" originalFilename="49694 PANORAMA WP3 – Healthcare PIS v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP3 – Healthcare PIS v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="253412" md5sum="3ebf145b4440746a8ae06733c7764f3b"/>
	<description>WP3 (Healthcare)</description>
	<productionNotes/>
      </output>
      <output id="23b88566-8d40-4a14-ab0a-c8d6b438f0f5" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="cfc4980b-08c2-441e-aac5-bb5219f4839a" originalFilename="49694 PANORAMA WP4 - Participant Information Sheet v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP4 - Participant Information Sheet v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="250114" md5sum="ef709faad49a914d4bcf913e4b0b8b69"/>
	<description>WP4</description>
	<productionNotes/>
      </output>
      <output id="104c905e-6b19-4397-9d26-daa10ee825d9" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="d3ba6b4f-65ec-47eb-9025-005344c01869" originalFilename="49694 PANORAMA WP5 - Participant Information Sheet (Carer) v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP5 - Participant Information Sheet (Carer) v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="257031" md5sum="edda5912aa2bbb878b1cce268a8123b2"/>
	<description>WP5 (Carer)</description>
	<productionNotes/>
      </output>
      <output id="bc9ee307-6025-478c-9dd6-b05250eaccda" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="6a625896-ebb4-4e20-b995-e0bc91f924f8" originalFilename="49694 PANORAMA WP5 – Healthcare PIS v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP5 – Healthcare PIS v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="260109" md5sum="cfec9b3b67e8c1ec5e6999c60d96c23d"/>
	<description>WP5 (Healthcare)</description>
	<productionNotes/>
      </output>
      <output id="8d09ee35-cafd-4b03-a1c2-8f4f1895df47" outputType="pis" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="b01b09f5-7cea-4a8f-bddb-15f3375ce1a8" originalFilename="49694 PANORAMA WP5 - Participant Information Sheet (Patient) v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA WP5 - Participant Information Sheet (Patient) v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="255957" md5sum="e5a8194c9a60351c48a8141029509917"/>
	<description>WP5 (Patient)</description>
	<productionNotes/>
      </output>
      <output id="74e800d3-ebf8-4e20-9957-e0f0f42494bb" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-05-11T00:00:00.000Z" dateUploaded="2026-06-22T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="140b17b8-7b62-4c82-b570-191a56b5aaa3" originalFilename="49694 PANORAMA PROTOCOL v1.1 (11-May-2026).pdf" downloadFilename="49694 PANORAMA PROTOCOL v1.1 (11-May-2026).pdf" version="1.1" mimeType="application/pdf" length="1274826" md5sum="7d45197443eb0e6122b78f0d75c18bdd"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>a8302537-1fc8-48d8-bf9b-8017a0a1efa7</funderId>
      <contactId>45a86941-ef30-4088-9da9-fc9a6a7ec9e6</contactId>
      <contactId>4139f118-08af-43cf-b57e-17f39dd608da</contactId>
      <sponsorId>a99f577c-dde0-44d1-bfda-2b0d5029b807</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/b48a81a5-d3ce-4331-aaaa-6646e60da2c1/49694">
	<description>WP2 (Carer)</description>
	<name>49694 PANORAMA WP2 - PIS (Carer) v1.1 (11-May-2026).pdf</name>
	<id>b48a81a5-d3ce-4331-aaaa-6646e60da2c1</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>248523</length>
	<md5sum>0c2c4fce06c569ab0039972ad46c69fe</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/a63d6196-1b78-491d-b4ef-7ad6d6509732/49694">
	<description>WP2 (Patient)</description>
	<name>49694 PANORAMA WP2 - PIS (Patient) v1.1 (11-May-2026).pdf</name>
	<id>a63d6196-1b78-491d-b4ef-7ad6d6509732</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>247988</length>
	<md5sum>86bc26aef761125d83fa7228ae598af0</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/02eea570-22d3-4672-860a-8cb32432bd6b/49694">
	<description>WP3 (Healthcare)</description>
	<name>49694 PANORAMA WP3 – Healthcare PIS v1.1 (11-May-2026).pdf</name>
	<id>02eea570-22d3-4672-860a-8cb32432bd6b</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>253412</length>
	<md5sum>3ebf145b4440746a8ae06733c7764f3b</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/cfc4980b-08c2-441e-aac5-bb5219f4839a/49694">
	<description>WP4</description>
	<name>49694 PANORAMA WP4 - Participant Information Sheet v1.1 (11-May-2026).pdf</name>
	<id>cfc4980b-08c2-441e-aac5-bb5219f4839a</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>250114</length>
	<md5sum>ef709faad49a914d4bcf913e4b0b8b69</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/6a625896-ebb4-4e20-b995-e0bc91f924f8/49694">
	<description>WP5 (Healthcare)</description>
	<name>49694 PANORAMA WP5 – Healthcare PIS v1.1 (11-May-2026).pdf</name>
	<id>6a625896-ebb4-4e20-b995-e0bc91f924f8</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>260109</length>
	<md5sum>cfec9b3b67e8c1ec5e6999c60d96c23d</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/d3ba6b4f-65ec-47eb-9025-005344c01869/49694">
	<description>WP5 (Carer)</description>
	<name>49694 PANORAMA WP5 - Participant Information Sheet (Carer) v1.1 (11-May-2026).pdf</name>
	<id>d3ba6b4f-65ec-47eb-9025-005344c01869</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>257031</length>
	<md5sum>edda5912aa2bbb878b1cce268a8123b2</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/b01b09f5-7cea-4a8f-bddb-15f3375ce1a8/49694">
	<description>WP5 (Patient)</description>
	<name>49694 PANORAMA WP5 - Participant Information Sheet (Patient) v1.1 (11-May-2026).pdf</name>
	<id>b01b09f5-7cea-4a8f-bddb-15f3375ce1a8</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>255957</length>
	<md5sum>e5a8194c9a60351c48a8141029509917</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/140b17b8-7b62-4c82-b570-191a56b5aaa3/49694">
	<description>Protocol file</description>
	<name>49694 PANORAMA PROTOCOL v1.1 (11-May-2026).pdf</name>
	<id>140b17b8-7b62-4c82-b570-191a56b5aaa3</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>1274826</length>
	<md5sum>7d45197443eb0e6122b78f0d75c18bdd</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="45a86941-ef30-4088-9da9-fc9a6a7ec9e6">
    <title>Dr</title>
    <forename>Michala</forename>
    <surname>Pettitt</surname>
    <orcid>https://orcid.org/0000-0002-4736-259X</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Public Health Building
University of Birmingham</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 121 415 9106</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">panorama-study@contacts.bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="4139f118-08af-43cf-b57e-17f39dd608da">
    <title>Mr</title>
    <forename>Matt</forename>
    <surname>Lee</surname>
    <orcid>https://orcid.org/0000-0001-9971-1635</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Public Health Building
University of Birmingham</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.j.lee.1@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="a99f577c-dde0-44d1-bfda-2b0d5029b807">
    <organisation>University of Birmingham</organisation>
    <sponsorType>University/education</sponsorType>
    <rorId>https://ror.org/03angcq70</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="a8302537-1fc8-48d8-bf9b-8017a0a1efa7">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-09-25T12:56:46.691250428Z" version="15" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN17096714" publicIdentifierDateAssigned="2026-07-14T08:54:13.573798Z">
    <isrctn dateAssigned="2026-07-14T08:54:13.573798Z">17096714</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Improving care for people admitted with diabetes-related emergencies</title>
      <scientificTitle>Developing a patient-physician co-created national diabetes-related emergencies management monitoring model</scientificTitle>
      <acronym>DEKODE</acronym>
      <studyHypothesis>1. To determine variations and inequalities in diabetes-related emergencies care outcomes in the UK across age, sex, ethnicity, deprivation, region, and vulnerable populations
2. To understand the experiences of people and their carers who have been treated for diabetes-related emergencies
3. To identify implementation principles for patient-centred care in people admitted with diabetes-related emergencies and through DEKODE
4. To investigate the predictors, clinical outcomes, and healthcare impact of recurrent diabetes-related emergencies episodes
5. To evaluate the cost-effectiveness of the DEKODE initiative</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Diabetic ketoacidosis (DKA) is a dangerous condition where the body lacks enough insulin, causing high blood sugar and acid levels. It's one of the most common reasons people with diabetes need emergency hospital care, with over 32,000 UK cases last year costing the NHS more than £90 million. If untreated, DKA can be life-threatening.
In 2020, researchers developed DEKODE, a digital tool helping hospitals track and improve DKA care. Early results showed care varies widely, even within the same hospital, but the reasons are unclear, and patient views haven't been captured. This study aims to understand why DKA care varies across the UK, explore patient and staff experiences, improve the DEKODE tool, investigate repeat DKA episodes, and assess whether DEKODE saves the NHS money

Who can participate?
1. Patients admitted to hospital with DKA (using anonymised hospital records from 2001 onwards)
2. Patients aged 16-99 years recently treated for DKA at University Hospitals Birmingham, and their carers
3. Healthcare professionals involved in DKA care at hospitals using DEKODE across the UK

What does the study involve?
The study has five parts: analysing anonymised NHS hospital records to see how DKA rates and outcomes differ by age, sex, ethnicity, deprivation and region; inviting patients, carers and staff to complete questionnaires and optional video interviews about their experiences; interviewing staff at hospitals using DEKODE to understand what helps or hinders its use; studying hospital data on people who've had DKA more than once; and calculating NHS treatment costs and whether DEKODE reduces them over time.
No new treatments are tested – the study focuses on experiences, care patterns and costs.

What are the possible benefits and risks of participating?
The risks are low to none. However, talking about a DKA episode may bring up difficult memories for some patients or carers. Information to seek support from a relevant patient support group (e.g., Diabetes UK) will be provided if needed. Participants won't directly benefit, but the study will help improve future DKA care.

Where is the study run from?
University of Birmingham. The wider DEKODE project involves hospitals across the UK.

When is the study starting and how long is it expected to run for?
June 2025 to August 2028

Who is funding the study?
NIHR Academy, via an NIHR Advanced Fellowship awarded to Dr Punith Kempegowda

Who is the main contact?
Dr Punith Kempegowda, p.kempegowda@bham.ac.uk</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>Work Package 1 – Assessing inequities in DKA care and outcomes in the UK
Objective 1.1: Crude incidence rate of DKA (number of new cases per 100,000 person-years), measured using CPRD Aurum/GOLD linked to HES (ICD-10 codes E10.0–E14.1), calculated annually from 01/01/2001 to 31/12/2023, stratified by age, sex, ethnicity, deprivation, mental health status, and region.
Objective 1.2: Length of hospitalisation, measured using HES data, at the index DKA admission.

Work Package 2 – Lived experiences of people treated for and treating DKA
Patient-reported experience of DKA care, measured using the NHS Inpatient Questionnaire for people with diabetes (Microsoft Forms) and the EQ-5D-Y questionnaire, at baseline (inpatient admission), 3 months and 6 months post-discharge.

Work Package 3 – DEKODE model implementation and effectiveness
Variation in DEKODE implementation across NHS Trusts, measured using thematic analysis of semi-structured interviews with stakeholders (applying NASSS and CFIR frameworks), at the time of interview across six consecutive quarterly DEKODE data cycles.

Work Package 4 – Investigating recurrent DKA
Frequency and predictors of recurrent DKA (defined as ≥2 DKA episodes), measured using pseudonymised DEKODE national audit data and NHS hospital records, across the full study period.

Work Package 5 – Health economics evaluation of the DEKODE model
Cost of managing a single DKA episode, measured using NHS procurement data and DEKODE audit data (direct and indirect costs), at baseline and at 12, 18, and 24 months after DEKODE adoption in participating institutions.</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>There are no secondary outcomes</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="4f7f0aa9-9bbc-45cd-86c4-afca40a95778" approvalStatus="approved" statusDate="2025-06-23T00:00:00.000Z">
	  <committeeName>HRA and Health and Care Research Wales (HCRW)</committeeName>
	  <contactDetails>
	    <address>Health Research Authority, 2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>25/IEC08/0011</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN17096714</doi>
      <eudraCTNumber/>
      <irasNumber>344284</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 56443, NIHR: 303671</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="5a501c3e-f198-414e-ad16-36c8b3f1e8f8" numberType="iras" canonicalSecondaryNumber="IRAS344284">344284</secondaryNumber>
	<secondaryNumber id="402f48d6-fc76-491a-a67c-06844f64961f" numberType="cpms" canonicalSecondaryNumber="CPMS56443">56443</secondaryNumber>
	<secondaryNumber id="36332fcb-0d65-4f43-a250-84caac00b843" numberType="nihr" canonicalSecondaryNumber="NIHR303671">303671</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-component, mixed-methods study programme</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2028-08-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a62fe3a6-3c21-489b-999a-ad04a79aad40">
	  <name>University of Birmingham</name>
	  <address>Department of Applied Health Sciences
Murray Learning Centre</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B15 2TT</zip>
	</trialCentre>
	<trialCentre id="e0ca109e-6a7a-4617-a5cc-88642c72bb1d">
	  <name>University Hospitals Birmingham NHS Foundation Trust</name>
	  <address>Queen Elizabeth Hospital
Mindelsohn Way
Edgbaston</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B15 2GW</zip>
	  <rtsId>RRK@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>Work Package 1: 
Patients admitted with DKA from 1 January 2001 to 31 December 2023.

Work Package 2:
1. Patients:
1.1. Those admitted to the hospital with DKA
1.2. Have the capacity to provide consent
1.3. Aged 16-99 years

2. Carers:
2.1. Those who are identified by patients as recruited above
2.2. Have the capacity to provide consent
2.3. Aged 16-99 years

3. Healthcare workers:
3.1. Those involved in treating DKA for patients recruited above
3.2. Have the capacity to provide consent

Work Package 3: 
Healthcare professionals involved in providing DKA care in hospitals participating in DEKODE</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="16.0">16 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="99.0">99 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>Work Package 1: 
Individuals with non-diabetic ketoacidosis or other metabolic disorders that could confound the study results

Work Package 2:
1. Patients without DKA
2. Providers not directly involved in DKA care
3. Unable to provide consent

Work Package 3:
Individuals who do not have sufficient interaction with the DKA care process</exclusion>
      <recruitmentStart>2025-06-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes mellitus</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The DEKODE study is designed to improve the care of people admitted to hospital with diabetes-related emergencies. It consists of four work packages, each focusing on a specific aspect of DKA care. Below is a summary of what will happen to participants in each work package, presented in a clear and straightforward way.

Work Package 1: Understanding Inequalities in DKA Care
We will use anonymised health records of patients with DKA from 2001 to 2023 to study differences in care and outcomes across regions, age groups, ethnicities, and other factors.
This part of the study does not involve direct interaction with participants.

Work Package 2: Exploring Lived Experiences of Patients, Carers, and Healthcare Professionals

Patients:
Patients treated for DKA will be invited to complete a short online questionnaire about their hospital experience.
Some patients will be invited for a one-on-one online interview lasting about 30 minutes, where they can share their experiences before, during, and after their hospital stay.
A follow-up questionnaire will be sent to patients 3 and 6 months after their discharge to understand any changes in their health and recovery.

Carers:
Carers (e.g., family members or friends) identified by the patients with their consent will also be invited to participate.
They will be interviewed separately to share their perspective on supporting someone with DKA.

Healthcare professionals:
Healthcare professionals involved in DKA care (e.g., doctors, nurses, and specialist teams) will be invited to take part in online interviews or focus groups. These will last about 30–60 minutes and explore their experiences in managing DKA.
All interviews and focus groups will take place online (e.g., via Zoom) and will be audio-recorded.

Work Package 3: Evaluating the Implementation of the DEKODE Model
Researchers will study how hospitals across the UK have adopted the DEKODE model for standardising DKA care.
Healthcare professionals from hospitals using the DEKODE system will be invited for interviews or focus groups to discuss the following:
1. How the model is being used in their hospital.
2. Any challenges or successes in implementing the system.
Around 20–30 professionals will participate in this part of the study.

Work Package 4: Investigating Recurrent DKA: A Retrospective Cohort Analysis Using DEKODE
This retrospective cohort study will analyse individuals with ≥2 DKA episodes using DEKODE data and hospital records to identify key clinical determinants, risk factors, and healthcare utilisation patterns associated with recurrent
DKA. Statistical analyses, including logistic regression and Kaplan-Meier survival analysis, will assess independent predictors of recurrence, clinical outcomes, and the impact of DEKODE implementation on reducing recurrence rates

Work Package 5: Health Economics Evaluation
Researchers will analyse the financial impact of using the DEKODE model in hospitals by comparing the cost of DKA care before and after its implementation.
This part will rely on anonymised hospital data and does not involve any interaction with participants.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study will be available upon request from Punith Kempegowda (p.kempegowda@bham.ac.uk).
Type of data: Qualitative 
When the data will become available and for how long: 2029, 4 years
By what access criteria data will be shared, including with whom: requests will be reviewed case-by-case, and data will be shared upon reasonable request
For what types of analyses: secondary qualitative analysis
What mechanism? Researchers wishing to access the pseudonymised dataset must submit a written request to the Chief Investigator (Dr Punith Kempegowda, p.kempegowda@bham.ac.uk), outlining the proposed analysis. These will then be reviewed on a case-by-case basis and access will require a signed data-sharing agreement with the University of Birmingham. 
Whether consent from participants was obtained: Yes
Comments on data anonymisation: Only anonymised data will be provided
Any ethical or legal restrictions: the requesting researcher should have appropriate ethical and legal approval to request data for further analysis.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Available on request</dataPolicy>
      </dataPolicies>
      <publicationDetails>2026 Protocol article in https://pubmed.ncbi.nlm.nih.gov/42780780/ (added 25/09/2026)</publicationDetails>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e68b325b-f42e-4748-bc3f-0df8d1d47244" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2026-09-09T00:00:00.000Z" dateUploaded="2026-09-25T00:00:00.000Z" peerReviewed="true" patientFacing="false" createdBy="">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/42780780/"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="c9b582f4-fd07-4117-a23d-eb768b101911" outputType="protocolfile" artefactType="LocalFile" dateCreated="2025-07-11T00:00:00.000Z" dateUploaded="2026-07-02T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="1143fb90-d300-4b9a-a71c-58aab1f1f4c0" originalFilename="49713_PROTOCOL.pdf" downloadFilename="49713_PROTOCOL.pdf" version="2.0" mimeType="application/pdf" length="753154" md5sum="dd85f35cabcc811841bb4b8f1191aa5b"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>8feb4b65-f215-4641-8996-105f06af3cf8</funderId>
      <contactId>ba74f382-4dab-4281-80d3-19ab3d1c6b9a</contactId>
      <contactId>3f8e855a-f000-491f-9478-7414f2d944dc</contactId>
      <sponsorId>355e8323-3f92-4392-b987-ef681fa9fca6</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/1143fb90-d300-4b9a-a71c-58aab1f1f4c0/49713">
	<description>Protocol file</description>
	<name>49713_PROTOCOL.pdf</name>
	<id>1143fb90-d300-4b9a-a71c-58aab1f1f4c0</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>753154</length>
	<md5sum>dd85f35cabcc811841bb4b8f1191aa5b</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="ba74f382-4dab-4281-80d3-19ab3d1c6b9a">
    <title>Dr</title>
    <forename>Punith</forename>
    <surname>Kempegowda</surname>
    <orcid>https://orcid.org/0000-0003-0954-6512</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Applied Health Sciences, University of Birmingham</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)7721 930777</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.kempegowda@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="3f8e855a-f000-491f-9478-7414f2d944dc">
    <title>Dr</title>
    <forename>Kalyaani</forename>
    <surname>Persad</surname>
    <orcid>https://orcid.org/0009-0009-1816-2909</orcid>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Applied Health Sciences, University of Birmingham</address>
      <city>Birmingham</city>
      <state/>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)7584811046</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">k.persad@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="355e8323-3f92-4392-b987-ef681fa9fca6">
    <organisation>University of Birmingham</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/03angcq70</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="8feb4b65-f215-4641-8996-105f06af3cf8">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial></allTrials>